• Sweden closing Nordsteam investigation a shocking coverup, investigator tells Grayzone

    Watch the Grayzone’s Max Blumenthal interview Swedish engineer Erik Andersson, who led the first independent investigation to the site of the Nordstream pipelines blast sites, on the Swedish government’s sudden closing of the investigation into the terror attack on the eve of joining NATO.

    Andersson also addresses US meddling in Swedish politics, and the potential consequences of Stockholm surrendering its traditional neutrality to the anti-Russian alliance.

    Full interview here.
    Sweden closing Nordsteam investigation a shocking coverup, investigator tells Grayzone Watch the Grayzone’s Max Blumenthal interview Swedish engineer Erik Andersson, who led the first independent investigation to the site of the Nordstream pipelines blast sites, on the Swedish government’s sudden closing of the investigation into the terror attack on the eve of joining NATO. Andersson also addresses US meddling in Swedish politics, and the potential consequences of Stockholm surrendering its traditional neutrality to the anti-Russian alliance. Full interview here.
    0 Comentários 0 Compartilhamentos 452 Visualizações
  • How To Perform Solat Terawih - Step by Step Guide
    Terawih is a beautiful and rewarding prayer that is only offered during the month of Ramadan. By learning how to pray Terawih, you strengthen your connection with Allah and contribute to the spirit of unity and devotion in the community. Don't miss this opportunity to gain blessings and make the most of Ramadan.

    Muslim.Sg is a one-stop online media platform that aims to inspire and empower millennial Muslims with powerful and engaging Islamic religious content.

    2024-03-08 • 14 min read

    How To Pray Terawih - Step-by-Step Guide

    How to Pray Taraweeh step by step for Muslim

    Praise be to Allah.

    One of the acts of worship that we all look forward to during Ramadan is the terawih prayer. The Prophet Muhammad s.a.w. said:

    مَنْ قَامَ رَمَضَانَ إِيْمَانًا وَاحْتِسَابًا غُفِرَ لَهُ مَا تَقَدَّمَ مِنْ ذَنْبِهِ

    “Whoever stands (in worship) in Ramadan out of faith and hope for the rewards (from Allah), his past sins will be forgiven.”

    (Sahih Al-Bukhārī & Muslim)

    The terawih prayer will begin right after the congregational Isyak prayer. Dedicated spaces for Muslimah will also be made available at most mosques.

    Read: 5 Things You Need to Know About Terawih Prayer.

    Want to refresh your memory on how to perform the terawih prayer? Here is a step-by-step guide that you can follow!

    1. Establish the intention to perform terawih

    how to taraweeh at home

    Recite the intention for terawih prayer:

    أُصَلِّي سُنَّةَ التَراوِيحِ رَكعَتَينِ لِلَّهِ تَعَالَى

    Usolli sunnata-taraawiihi rak'ataini lillah ta'ala

    I intend to pray the Sunnah prayer of terawih two raka'at for Allah ta'ala

    If you pray in a congregation, the intentions for terawih prayer are as follows. The one who is leading the prayer as an Imam would recite:

    أُصَلِّي سُنَّةَ التَراوِيحِ رَكعَتَينِ إِمَامًا لِلَّهِ تَعَالَى

    Usolli sunnata-taraawiihi rak'ataini imaamam lillah ta'ala

    I intend to pray the Sunnah prayer of terawih as the Imam two raka'at for Allah ta'ala

    The Makmum (follower) will recite this intention:

    أُصَلِّي سُنَّةَ التَراوِيحِ رَكعَتَينِ مَأمُومًا لِلَّهِ تَعَالَى

    Usolli sunnata-taraawiihi rak'ataini makmumam lillah ta'ala

    I intend to pray the Sunnah prayer of terawih as the Makmum two raka'at for Allah ta'ala

    The following illustrations will guide us in praying Jema’ah (in a congregation) at home:

    Guidelines for congregational prayer for Muslims at home

    Read: Guidelines for praying in a congregation.

    2. Say the Takbiratul Ihram

    how to taraweeh at home

    Takbiratul Ihram is the act of entering the state of prayer. It is done by raising your hands such that your thumbs are on the same level as your earlobes and your palms are on the same level as your shoulder.

    Say ‘Allahu Akbar’ while keeping your intention in mind.

    3. Place your right hand over your left hand and recite Dua Iftitah

    Stand in prayer (for the able men and women). Upon giving the Takbir, lower your hands gently over your chest and put your right hand over your left.

    Recite the Dua Iftitah (opening dua) quietly only for the first raka’at:

    اللهُ أَكْبَرُ كَبِيرًا وَالْحَمْدُ لِلَّهِ كَثِيْرًا وَسُبْحَانَ اللهِ بُكْرَةً وَأَصِيْلًا .وَجَّهْتُ وَجْهِيَ لِلَّذِيْ فَطَرَالسَّمَاوَاتِ وَالْأَرْضَ حَنِيْفًا مُسْلِمًا وَمَا أَنَا مِنَ الْمُشْرِكِيْنَ . إِنَّ صَلَاتِيْ وَنُسُكِيْ وَمَحْيَايَ وَمَمَاتِيْ لِلَّهِ رَبِّ الْعَالَمِيْنَ لاَ شَرِيْكَ لَهُ وَبِذَلِكَ أُمِرْتُ وَأنَا مِنَ الْمُسْلِمِيْنَ

    ______

    Allāhu Akbar Kabirā,
    Walhamdulillāhi Kathīrā
    Wa Subhānallāhi Bukratan Wa aṣīlā
    Wajjahtu Wajhiya lillazi Fatras-Samāwāti wal-Ardh
    Hanīfan Musliman Wa-mā ana minal-musyrikīn
    Inna ṣalātī, wa-nusukī wa-mahyaya, wamamātī Lillāhi Rabbil-'ālamīn
    Lā syarīka laHu wa bizālika umirtu wa ana minal muslimīn

    ______

    Allah the Almighty, the Greatest
    All praises be upon Him
    Allah The Most Exalted, day and night
    I stand before The One Who created the skies and the lands
    I sincerely submit to Allah and I am certainly not among those who associate Allah with other beings
    Indeed my Solat, my good deeds, my life and my death are all for Allah The Lord of all the worlds
    He has no partner nor parallel whatsoever, and I have been ordered as such, and I am from those who embrace Islam (submits).

    how to taraweeh at home

    4. Recite Surah Al-Fatihah and another Surah from the Quran

    Once the Dua Iftitah is read, recite the Ta’awwudz (seeking Allah's refuge from the devil) quietly:

    أَعُوذُ بِاللَّهِ مِنْ الشَّيْطَانِ الرَّجِيمِ

    A'uzu biLlāhi minash-shaytānir-rajim

    I seek refuge with Allah from the accursed Shaytan

    And then read Surah Al-Fatihah:

    بِسمِ اللَّهِ الرَّحمٰنِ الرَّحيمِ. الحَمدُ لِلَّهِ رَبِّ العالَمينَ
    الرَّحمٰنِ الرَّحيمِ. مالِكِ يَومِ الدّينِ
    إِيّاكَ نَعبُدُ وَإِيّاكَ نَستَعينُ
    اهدِنَا الصِّراطَ المُستَقيمَ
    صِراطَ الَّذِينَ أَنعَمتَ عَلَيهِم غَيرِ المَغضُوبِ عَلَيهِم وَلَا الضَّالِّينَ

    ______

    Bismillāhir-Raḥmānir-Raḥīm
    Alḥamdulillāhi Rabbil-ʿālamīn
    Ar-Raḥmānir-Raḥīm
    Māliki yawmid-dīn
    iyyāKa naʿbudu wa-iyyāKa nastaʿīn
    Ihdināṣ-ṣirāṭal-mustaqīm
    ṣirāṭallazīna anʿamta ʿalayhim ghayril-maghḍūbi ʿalayhim wa-lāḍḍāllīn

    ______

    In the name of God The Most Compassionate and Merciful
    Praise be to Allah, Lord of all the worlds
    The Compassionate, The Merciful. Ruler on the Day of Reckoning
    You alone do we worship, and You alone do we ask for help
    Guide us along the straight path
    the path of those on whom You have bestowed Your Grace
    not those You are displeased with, or those who are astray
    Amiin

    Upon completing the recitation of Surah Al-Fatihah, you may read any memorised surah of your preference. For the second raka’at, it is encouraged to choose a verse that does not precede the first in the order of the Quran.

    For example, you can read Surah Al-’Asr in the first raka’at and read Surah Al-Ikhlas in the second.

    Here is a list of recommended surahs from page 34 of Contemporary Irsyad Series - Ramadan edition (English) by Office of the Mufti:

    Recommended surah in terawih prayer

    While there is no harm in reading the same surah again for the next raka’at, this Ramadan could be an opportunity to learn other beautiful surah and further increase our appreciation of the Quran, especially since there are so many benefits of reciting the Quran.

    You may also opt to read from the Mushaf (physical copy of Quran), maybe a pocket Quran or Quran app.

    5. Bend forward for Ruku’

    Recite the Takbiratul Intiqal (Allahu Akbar) during the transition from standing to bending for Ruku’, while raising your hands just as previously explained in Takbiratul Ihram. Lower your hands gently to your knees as you move towards the Ruku’ position.

    Say three times,

    سُبحَانَ رَبِّيَ العَظِيمِ وَبِحَمْدِهِ

    Subhanna Rabbiyal-’azim wa bihamdiHi

    Glory be to Allah, the Mighty, and praise be to He

    how to pray taraweeh

    6. Stand in the upright position - I’tidal

    After completing your Ruku’, return to the standing position while raising your hands just as in the Takbiratul Ihram position and recite during the transition:

    سَمِعَ اللهُ لِمَنْ حَمِدَهُ

    Sami’ Allahu liman hamida

    Allah has heard the one who praised Him

    Lower your hands gently. When you are in the complete upright position, recite:

    رَبَّنَا وَلَكَ الْحَمْدُ

    Rabbana walaKal-hamd

    O Our Lord, to You are all the praises

    7. Perform the first sujud

    Go into prostration while saying the Takbiratul Intiqal (Allahu Akbar) without raising your hands. Let your knees touch the ground first, followed by your palms and then your forehead. While in the first Sujud, say three times:

    سُبْحَانَ رَبِّيَ الأَعْلَى وَبِحَمْدِهِ

    Subhānna Rabbiyal-a’lā wa bihamdih

    Glory be to my Lord The Most High, and praise be to He

    8. Sit on your knees

    In between the two Sujud, rise from prostration to a sitting position on your knees while saying the Takbiratul Intiqal without raising your hands. In the sitting position, say :

    رَبِّ اغْفِرْ لِيْ وَارْحَمْنِيْ وَاجْبُرْنِيْ وَارْفَعْنِيْ وَارْزُقْنِيْ وَاهْدِنِيْ وَعَافِنِيْ وَاعْفُ عَنِّيْ

    Rabbighfirlī warhamnī wajburnī warfa’nī warzuqnī wahdinī wa‘afinī wa’fu ‘annī

    O Lord, forgive me, have mercy on me, cover for me my shortcomings, elevate my rank, provide for me, guide me, grant me well-being, and pardon me

    9. Perform the second sujud

    Afterwards, return to the prostration position to complete the second Sujud and repeat the recitation as mentioned previously. Upon fulfilling the mentioned integrals (arkān), we have completed the first raka’at.

    10. Return to the standing position

    Return to the standing position as you recite the Takbiratul Intiqal and repeat the steps from 4 to 9 again to fulfil the second raka’at.

    11. Recite the final Tasyahhud

    At the end of your 2nd raka'at, sit on your left leg while the left foot is placed and briefly exposed below your right leg. Keep your right foot upright just as in the picture shown above. Complete the prayer by reciting the final Tasyahhud;

    اَلتَّحِيَّاتُ الْمُبَارَكَاتُ الصَّلَوَاتُ الطَّيِّبَاتُ ِللهِ. اَلسَّلاَمُ عَلَيْكَ أَيُّهَا النَّبِيُّ وَرَحْمَةُ اللهِ وَبَرَكَاتُهُ. اَلسَّلاَمُ عَلَيْنَا وَعَلَى عِبَادِ اللهِ الصَّالِحِيْنَ

    “At-tahiyyātul mubārakatuṣ-ṣalawātuth ṭayyibātu lillāh. Assalāmu ‘alaika ayyuhan-nabiyyu wa rahmatullāhi wa barakātuhu. Assalāmu ‘alainā wa ‘alā ‘ibādillāhiṣ-ṣālihīn.

    Raise your right index finger. And say:

    أَشْهدُ أَنْ لاَ إِلَهَ إِلاَّ اللهُ وَأَشْهَدُ أَنَّ مُحَمَّدًا رَسُوْلُ اللهِ

    Asyhadu an lā ilāha illallāh, wa asyhadu anna Muhammadar Rasuulullāh

    Continue with the selawat:

    اللَّهُمَّ صَلِّ عَلَى مُحَمَّدٍ وَعَلَى آلِ مُحَمَّدٍ كَمَا صَلَّيْتَ عَلَى آلِ إِبْرَاهِيمَ إِنَّكَ حَمِيدٌ مَجِيدٌ، اللَّهُمَّ بَارِكْ علَى مُحَمَّدٍ وَعَلَى آلِ مُحَمَّدٍ كَمَا بَارَكْتَ عَلَى آلِ إِبْرَاهِيمَ إِنَّكَ حَمِيدٌ مَجِيدٌ

    Allahumma ṣalli 'ala Muhammadin, wa 'alā āli Muhammad, kamā ṣallaita 'ala 'āli Ibrāhīma, innaka Hamīdun Majīd. Allahumma bārik 'alā Muhammadin, wa 'alā āli Muhammad, kamā bārakta 'alā āli Ibrāhīma, innaka Hamīdun Majīd

    O Allah, bestow your blessings upon Muhammad and the family of Muhammad as you bestowed your blessings upon the family of Ibrahim. Indeed You are Praised and Glorious. O Allah, bless Muhammad and the family of Muhammad as You have blessed the family of Ibrahim. Indeed You are Praised and Glorious

    12. End with the salam

    Turn your head to both of your sides, starting from the right, such that your cheek can be seen by anyone behind you, and say

    السَّلَامُ عَلَيْكُم وَرَحْمَةُ الله

    Assalamu alaykum wa-rahmatullah

    Peace and Allah’s mercy be upon you

    By giving the salam, we have therefore completed one set of terawih prayer.

    Each terawih prayer consists of two raka’at. If you intend to pray 8 raka'at of terawih prayer, do 4 sets of 2 raka'at. If you intend to do 20 raka'at of terawih prayer, do 10 sets of terawih Prayer.

    Read: How to Pray in Islam: Step-By-Step Guide to Solat for Beginners

    13. Do the witr prayer

    how to taraweeh at home

    After completing the terawih prayer, it is encouraged to end the night with the witr prayer. Witr can also be performed after completing Qiyam al-Layl which refers to other supererogatory (sunnah) prayers that are done towards the end of the night or after waking up from sleep. This was mentioned by the Prophet s.a.w.:

    “Make the last of your prayers at night the witr prayer."

    (Sahih Bukhari)

    Witr prayer should be performed in an odd number of raka'at and is usually done in 3 raka'at. This is done by performing two raka’at of the same steps mentioned with the salam, and then followed by one raka’at with the salam to complete the three raka’at of the Witr prayer. The maximum number of raka’at for the sunnah witr prayer is 11 raka’at.

    14. Read recommended zikir and supplications

    how to taraweeh at home

    There are supplications that are often read in mosques after every terawih prayer. However, if you do not read them, it does not invalidate the prayer. Nonetheless, reciting them is definitely encouraged. (Read Page 36 of Contemporary Irsyad Series - Ramadan edition)

    What is important for us is to make full use of this blessed time and position to sincerely supplicate to Allah s.w.t. and express our love, hope, fear, regret, heart and soul to The One Who Hears, is Kind and Most Merciful to His servants.

    However, it is understandable that we sometimes find it hard to think of what to dua. For the supplications that are often read after terawih and witr prayers, you may refer to this list of beautiful duas for Ramadan.

    May this step-by-step guide on how to perform the terawih prayer benefit us. May this Ramadan be a more meaningful one, and may Allah s.w.t. accept our humble deeds. Ameen.

    Allah knows best.

    There are many benefits of praying in a congregation. To get your terawih questions answered, Ustaz Irwan Hadi, together with Ms Marina Yusoff and her family, share how you can do your terawih prayer at home:



    https://muslim.sg/articles/how-to-perform-solat-terawih-step-by-step-guide

    https://telegra.ph/How-To-Perform-Solat-Terawih---Step-by-Step-Guide-03-11
    How To Perform Solat Terawih - Step by Step Guide Terawih is a beautiful and rewarding prayer that is only offered during the month of Ramadan. By learning how to pray Terawih, you strengthen your connection with Allah and contribute to the spirit of unity and devotion in the community. Don't miss this opportunity to gain blessings and make the most of Ramadan. Muslim.Sg is a one-stop online media platform that aims to inspire and empower millennial Muslims with powerful and engaging Islamic religious content. 2024-03-08 • 14 min read How To Pray Terawih - Step-by-Step Guide How to Pray Taraweeh step by step for Muslim Praise be to Allah. One of the acts of worship that we all look forward to during Ramadan is the terawih prayer. The Prophet Muhammad s.a.w. said: مَنْ قَامَ رَمَضَانَ إِيْمَانًا وَاحْتِسَابًا غُفِرَ لَهُ مَا تَقَدَّمَ مِنْ ذَنْبِهِ “Whoever stands (in worship) in Ramadan out of faith and hope for the rewards (from Allah), his past sins will be forgiven.” (Sahih Al-Bukhārī & Muslim) The terawih prayer will begin right after the congregational Isyak prayer. Dedicated spaces for Muslimah will also be made available at most mosques. Read: 5 Things You Need to Know About Terawih Prayer. Want to refresh your memory on how to perform the terawih prayer? Here is a step-by-step guide that you can follow! 1. Establish the intention to perform terawih how to taraweeh at home Recite the intention for terawih prayer: أُصَلِّي سُنَّةَ التَراوِيحِ رَكعَتَينِ لِلَّهِ تَعَالَى Usolli sunnata-taraawiihi rak'ataini lillah ta'ala I intend to pray the Sunnah prayer of terawih two raka'at for Allah ta'ala If you pray in a congregation, the intentions for terawih prayer are as follows. The one who is leading the prayer as an Imam would recite: أُصَلِّي سُنَّةَ التَراوِيحِ رَكعَتَينِ إِمَامًا لِلَّهِ تَعَالَى Usolli sunnata-taraawiihi rak'ataini imaamam lillah ta'ala I intend to pray the Sunnah prayer of terawih as the Imam two raka'at for Allah ta'ala The Makmum (follower) will recite this intention: أُصَلِّي سُنَّةَ التَراوِيحِ رَكعَتَينِ مَأمُومًا لِلَّهِ تَعَالَى Usolli sunnata-taraawiihi rak'ataini makmumam lillah ta'ala I intend to pray the Sunnah prayer of terawih as the Makmum two raka'at for Allah ta'ala The following illustrations will guide us in praying Jema’ah (in a congregation) at home: Guidelines for congregational prayer for Muslims at home Read: Guidelines for praying in a congregation. 2. Say the Takbiratul Ihram how to taraweeh at home Takbiratul Ihram is the act of entering the state of prayer. It is done by raising your hands such that your thumbs are on the same level as your earlobes and your palms are on the same level as your shoulder. Say ‘Allahu Akbar’ while keeping your intention in mind. 3. Place your right hand over your left hand and recite Dua Iftitah Stand in prayer (for the able men and women). Upon giving the Takbir, lower your hands gently over your chest and put your right hand over your left. Recite the Dua Iftitah (opening dua) quietly only for the first raka’at: اللهُ أَكْبَرُ كَبِيرًا وَالْحَمْدُ لِلَّهِ كَثِيْرًا وَسُبْحَانَ اللهِ بُكْرَةً وَأَصِيْلًا .وَجَّهْتُ وَجْهِيَ لِلَّذِيْ فَطَرَالسَّمَاوَاتِ وَالْأَرْضَ حَنِيْفًا مُسْلِمًا وَمَا أَنَا مِنَ الْمُشْرِكِيْنَ . إِنَّ صَلَاتِيْ وَنُسُكِيْ وَمَحْيَايَ وَمَمَاتِيْ لِلَّهِ رَبِّ الْعَالَمِيْنَ لاَ شَرِيْكَ لَهُ وَبِذَلِكَ أُمِرْتُ وَأنَا مِنَ الْمُسْلِمِيْنَ ______ Allāhu Akbar Kabirā, Walhamdulillāhi Kathīrā Wa Subhānallāhi Bukratan Wa aṣīlā Wajjahtu Wajhiya lillazi Fatras-Samāwāti wal-Ardh Hanīfan Musliman Wa-mā ana minal-musyrikīn Inna ṣalātī, wa-nusukī wa-mahyaya, wamamātī Lillāhi Rabbil-'ālamīn Lā syarīka laHu wa bizālika umirtu wa ana minal muslimīn ______ Allah the Almighty, the Greatest All praises be upon Him Allah The Most Exalted, day and night I stand before The One Who created the skies and the lands I sincerely submit to Allah and I am certainly not among those who associate Allah with other beings Indeed my Solat, my good deeds, my life and my death are all for Allah The Lord of all the worlds He has no partner nor parallel whatsoever, and I have been ordered as such, and I am from those who embrace Islam (submits). how to taraweeh at home 4. Recite Surah Al-Fatihah and another Surah from the Quran Once the Dua Iftitah is read, recite the Ta’awwudz (seeking Allah's refuge from the devil) quietly: أَعُوذُ بِاللَّهِ مِنْ الشَّيْطَانِ الرَّجِيمِ A'uzu biLlāhi minash-shaytānir-rajim I seek refuge with Allah from the accursed Shaytan And then read Surah Al-Fatihah: بِسمِ اللَّهِ الرَّحمٰنِ الرَّحيمِ. الحَمدُ لِلَّهِ رَبِّ العالَمينَ الرَّحمٰنِ الرَّحيمِ. مالِكِ يَومِ الدّينِ إِيّاكَ نَعبُدُ وَإِيّاكَ نَستَعينُ اهدِنَا الصِّراطَ المُستَقيمَ صِراطَ الَّذِينَ أَنعَمتَ عَلَيهِم غَيرِ المَغضُوبِ عَلَيهِم وَلَا الضَّالِّينَ ______ Bismillāhir-Raḥmānir-Raḥīm Alḥamdulillāhi Rabbil-ʿālamīn Ar-Raḥmānir-Raḥīm Māliki yawmid-dīn iyyāKa naʿbudu wa-iyyāKa nastaʿīn Ihdināṣ-ṣirāṭal-mustaqīm ṣirāṭallazīna anʿamta ʿalayhim ghayril-maghḍūbi ʿalayhim wa-lāḍḍāllīn ______ In the name of God The Most Compassionate and Merciful Praise be to Allah, Lord of all the worlds The Compassionate, The Merciful. Ruler on the Day of Reckoning You alone do we worship, and You alone do we ask for help Guide us along the straight path the path of those on whom You have bestowed Your Grace not those You are displeased with, or those who are astray Amiin Upon completing the recitation of Surah Al-Fatihah, you may read any memorised surah of your preference. For the second raka’at, it is encouraged to choose a verse that does not precede the first in the order of the Quran. For example, you can read Surah Al-’Asr in the first raka’at and read Surah Al-Ikhlas in the second. Here is a list of recommended surahs from page 34 of Contemporary Irsyad Series - Ramadan edition (English) by Office of the Mufti: Recommended surah in terawih prayer While there is no harm in reading the same surah again for the next raka’at, this Ramadan could be an opportunity to learn other beautiful surah and further increase our appreciation of the Quran, especially since there are so many benefits of reciting the Quran. You may also opt to read from the Mushaf (physical copy of Quran), maybe a pocket Quran or Quran app. 5. Bend forward for Ruku’ Recite the Takbiratul Intiqal (Allahu Akbar) during the transition from standing to bending for Ruku’, while raising your hands just as previously explained in Takbiratul Ihram. Lower your hands gently to your knees as you move towards the Ruku’ position. Say three times, سُبحَانَ رَبِّيَ العَظِيمِ وَبِحَمْدِهِ Subhanna Rabbiyal-’azim wa bihamdiHi Glory be to Allah, the Mighty, and praise be to He how to pray taraweeh 6. Stand in the upright position - I’tidal After completing your Ruku’, return to the standing position while raising your hands just as in the Takbiratul Ihram position and recite during the transition: سَمِعَ اللهُ لِمَنْ حَمِدَهُ Sami’ Allahu liman hamida Allah has heard the one who praised Him Lower your hands gently. When you are in the complete upright position, recite: رَبَّنَا وَلَكَ الْحَمْدُ Rabbana walaKal-hamd O Our Lord, to You are all the praises 7. Perform the first sujud Go into prostration while saying the Takbiratul Intiqal (Allahu Akbar) without raising your hands. Let your knees touch the ground first, followed by your palms and then your forehead. While in the first Sujud, say three times: سُبْحَانَ رَبِّيَ الأَعْلَى وَبِحَمْدِهِ Subhānna Rabbiyal-a’lā wa bihamdih Glory be to my Lord The Most High, and praise be to He 8. Sit on your knees In between the two Sujud, rise from prostration to a sitting position on your knees while saying the Takbiratul Intiqal without raising your hands. In the sitting position, say : رَبِّ اغْفِرْ لِيْ وَارْحَمْنِيْ وَاجْبُرْنِيْ وَارْفَعْنِيْ وَارْزُقْنِيْ وَاهْدِنِيْ وَعَافِنِيْ وَاعْفُ عَنِّيْ Rabbighfirlī warhamnī wajburnī warfa’nī warzuqnī wahdinī wa‘afinī wa’fu ‘annī O Lord, forgive me, have mercy on me, cover for me my shortcomings, elevate my rank, provide for me, guide me, grant me well-being, and pardon me 9. Perform the second sujud Afterwards, return to the prostration position to complete the second Sujud and repeat the recitation as mentioned previously. Upon fulfilling the mentioned integrals (arkān), we have completed the first raka’at. 10. Return to the standing position Return to the standing position as you recite the Takbiratul Intiqal and repeat the steps from 4 to 9 again to fulfil the second raka’at. 11. Recite the final Tasyahhud At the end of your 2nd raka'at, sit on your left leg while the left foot is placed and briefly exposed below your right leg. Keep your right foot upright just as in the picture shown above. Complete the prayer by reciting the final Tasyahhud; اَلتَّحِيَّاتُ الْمُبَارَكَاتُ الصَّلَوَاتُ الطَّيِّبَاتُ ِللهِ. اَلسَّلاَمُ عَلَيْكَ أَيُّهَا النَّبِيُّ وَرَحْمَةُ اللهِ وَبَرَكَاتُهُ. اَلسَّلاَمُ عَلَيْنَا وَعَلَى عِبَادِ اللهِ الصَّالِحِيْنَ “At-tahiyyātul mubārakatuṣ-ṣalawātuth ṭayyibātu lillāh. Assalāmu ‘alaika ayyuhan-nabiyyu wa rahmatullāhi wa barakātuhu. Assalāmu ‘alainā wa ‘alā ‘ibādillāhiṣ-ṣālihīn. Raise your right index finger. And say: أَشْهدُ أَنْ لاَ إِلَهَ إِلاَّ اللهُ وَأَشْهَدُ أَنَّ مُحَمَّدًا رَسُوْلُ اللهِ Asyhadu an lā ilāha illallāh, wa asyhadu anna Muhammadar Rasuulullāh Continue with the selawat: اللَّهُمَّ صَلِّ عَلَى مُحَمَّدٍ وَعَلَى آلِ مُحَمَّدٍ كَمَا صَلَّيْتَ عَلَى آلِ إِبْرَاهِيمَ إِنَّكَ حَمِيدٌ مَجِيدٌ، اللَّهُمَّ بَارِكْ علَى مُحَمَّدٍ وَعَلَى آلِ مُحَمَّدٍ كَمَا بَارَكْتَ عَلَى آلِ إِبْرَاهِيمَ إِنَّكَ حَمِيدٌ مَجِيدٌ Allahumma ṣalli 'ala Muhammadin, wa 'alā āli Muhammad, kamā ṣallaita 'ala 'āli Ibrāhīma, innaka Hamīdun Majīd. Allahumma bārik 'alā Muhammadin, wa 'alā āli Muhammad, kamā bārakta 'alā āli Ibrāhīma, innaka Hamīdun Majīd O Allah, bestow your blessings upon Muhammad and the family of Muhammad as you bestowed your blessings upon the family of Ibrahim. Indeed You are Praised and Glorious. O Allah, bless Muhammad and the family of Muhammad as You have blessed the family of Ibrahim. Indeed You are Praised and Glorious 12. End with the salam Turn your head to both of your sides, starting from the right, such that your cheek can be seen by anyone behind you, and say السَّلَامُ عَلَيْكُم وَرَحْمَةُ الله Assalamu alaykum wa-rahmatullah Peace and Allah’s mercy be upon you By giving the salam, we have therefore completed one set of terawih prayer. Each terawih prayer consists of two raka’at. If you intend to pray 8 raka'at of terawih prayer, do 4 sets of 2 raka'at. If you intend to do 20 raka'at of terawih prayer, do 10 sets of terawih Prayer. Read: How to Pray in Islam: Step-By-Step Guide to Solat for Beginners 13. Do the witr prayer how to taraweeh at home After completing the terawih prayer, it is encouraged to end the night with the witr prayer. Witr can also be performed after completing Qiyam al-Layl which refers to other supererogatory (sunnah) prayers that are done towards the end of the night or after waking up from sleep. This was mentioned by the Prophet s.a.w.: “Make the last of your prayers at night the witr prayer." (Sahih Bukhari) Witr prayer should be performed in an odd number of raka'at and is usually done in 3 raka'at. This is done by performing two raka’at of the same steps mentioned with the salam, and then followed by one raka’at with the salam to complete the three raka’at of the Witr prayer. The maximum number of raka’at for the sunnah witr prayer is 11 raka’at. 14. Read recommended zikir and supplications how to taraweeh at home There are supplications that are often read in mosques after every terawih prayer. However, if you do not read them, it does not invalidate the prayer. Nonetheless, reciting them is definitely encouraged. (Read Page 36 of Contemporary Irsyad Series - Ramadan edition) What is important for us is to make full use of this blessed time and position to sincerely supplicate to Allah s.w.t. and express our love, hope, fear, regret, heart and soul to The One Who Hears, is Kind and Most Merciful to His servants. However, it is understandable that we sometimes find it hard to think of what to dua. For the supplications that are often read after terawih and witr prayers, you may refer to this list of beautiful duas for Ramadan. May this step-by-step guide on how to perform the terawih prayer benefit us. May this Ramadan be a more meaningful one, and may Allah s.w.t. accept our humble deeds. Ameen. Allah knows best. There are many benefits of praying in a congregation. To get your terawih questions answered, Ustaz Irwan Hadi, together with Ms Marina Yusoff and her family, share how you can do your terawih prayer at home: https://muslim.sg/articles/how-to-perform-solat-terawih-step-by-step-guide https://telegra.ph/How-To-Perform-Solat-Terawih---Step-by-Step-Guide-03-11
    Like
    1
    0 Comentários 0 Compartilhamentos 3283 Visualizações
  • 🚨 Study Claims COVID Caused More Heart Damage Than Vaccines — Here’s What the Authors Got Wrong

    Rainer Johannes Klement, Ph.D + Harald Walach reanalyzed data and found that while coronaviruses might cause myocarditis, the COVID-19 vaccines cause at least as much or more.

    Study Claims COVID Caused More Heart Damage Than Vaccines — Here’s What the Authors Got Wrong
    A 2023 study admitted that the COVID-19 mRNA vaccines cause myocarditis, but claimed the COVID-19 virus was even more damaging than the vaccine. A recent, more detailed review of their data, however, showed the opposite is likely true.

    Angelo DePalma, Ph.D.
    human heart with covid vaccine
    Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.

    Despite the known side effects of mRNA COVID-19 vaccines, some studies (here, here and here) and health websites (here, here and here) argue that whatever vaccination’s adverse outcomes, being unvaccinated is worse.

    In one such study, Dr. Christian Mueller and his co-authors concluded the COVID-19 virus — not the vaccine — was responsible for more myocarditis, or heart muscle damage, than the vaccine.

    However, when Rainer Johannes Klement, Ph.D., a physicist at Leopoldina Hospital in Schweinfurt, Germany, and Harald Walach, a clinical psychologist and head of the Change Health Institute in Basel, Switzerland, reanalyzed Mueller’s data they found that while coronaviruses might cause myocarditis, the COVID-19 vaccines cause at least as much or more.

    The Klement paper appeared in the Feb. 1 edition of The Egyptian Health Journal.

    Mueller’s study

    Mueller set out to quantify and compare myocarditis in vaxed versus unvaxed subjects and to explain possible mechanisms.

    To explore these mechanisms, the researchers tested subjects for antibodies against interleukin-1 receptor antagonist (IL-1RA), the SARS-CoV-2-nucleoprotein, the viral spike protein and 14 inflammatory cytokines.

    Since none of these measures differed between study groups, the “mechanism” issue was unresolved.

    To assess myocarditis investigators tested 777 hospital workers (median age 37, 69.5% women) for cardiac troponin T one and three days after they received an mRNA-1273 booster. Cardiologists typically prescribe this test after a suspected heart attack to quantify the extent and duration of heart damage.

    Of the 40 subjects (5.1%) with elevated troponin on Day 3, 22 (2.8%) were diagnosed with myocarditis, with 20 cases occurring in women and two in men.

    The researchers reported that among these subjects troponin elevations were mild and temporary and did not involve abnormalities as determined by electrocardiogram. No patients experienced “major adverse cardiac events” within 30 days of receiving the shot.

    Mueller’s team concluded:

    COVID-19 associates with a substantially higher risk for myocarditis that [sic] mRNA vaccination …
    Myocarditis related to COVID-19 infection has shown a higher mortality than myocarditis related to mRNA vaccination.
    Before the COVID-19 vaccine were [sic] available, the incidence and extent of myocardial injury associated with COVID-19 infection was [sic] much higher than observed in this active surveillance study after booster vaccination.
    One of the Mueller co-authors had commercial ties to diagnostics companies. Another had previously been compensated by diagnostics and vaccine manufacturers. Mueller had relationships with diagnostics, pharmaceutical and vaccine companies at the time he wrote the paper.

    Where did Mueller go wrong?

    One way to measure treatment effects is to compare an outcome, for example, blood pressure, in the same subjects before and after the treatment and report before-and-after results.

    Although this option was known to medical researchers and available to him, Mueller did not take advantage of it — either because he did not think to measure pre-booster troponin levels or chose not to report them for some reason, perhaps because they did not align with his other results.

    Instead, his team took an approach that required two well-matched study groups. Although Mueller claimed placebos and controls met this requirement they differed on the feature that mattered most: heart health.

    Vaccinated subjects with current or recent heart issues were excluded from the study, while all control subjects had just entered the hospital with heart symptoms and were therefore already at greater risk for myocarditis.

    Klement and Walach found more anomalies in the Mueller paper.

    RFK Jr. and Brian Hooker Vax-Unvax
    RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax”

    Order Now

    They began their critique by citing three 2021 studies on COVID-19 vaccine-induced myocarditis (here, here and here). All three studies showed myocarditis became a concern shortly after the COVID-19 vaccine introductions.

    They discussed three papers in some detail:

    A 2023 German autopsy study on 25 unexpected deaths within 20 days of COVID-19 vaccination identified acute myocarditis as the most probable cause of death in four cases.
    A 2023 report on myocarditis in 303 non-vaccinated and 700 vaccinated asymptomatic subjects found significantly higher damage in the vaccinated persisting for up to 180 days post-vaccination.
    One of the first autopsy papers, an Indian-led study based on World Health Organization pharmacovigilance data reported 2.1 times the risk for cardiac arrest, 2.7 times the risk for acute heart attack, 2.6 times the risk for elevated troponin, and 7.3-fold higher levels of D-dimer for COVID-19 vaccinations compared with the use of other medications.
    These studies strongly suggest that myocarditis became an issue only after the mRNA vaccine rollouts. They contradict Mueller’s statement that the “extent of myocardial injury associated with COVID-19 infection was much higher than observed in this active surveillance study after booster vaccination.”

    According to Klement and Walach, this statement is wrong for two reasons.

    First, in addition to the non-equivalence of controls’ and subjects’ heart-health status, Mueller ignored the much larger number of COVID-19-infected, unhospitalized, unvaccinated individuals with (presumably) much lower troponin levels compared with patients entering the hospital with heart symptoms.

    Second, Klement and Walach argued that the public health impact of myocarditis depends not only on the incidence or rate among study groups but the size of those groups. The significance is that a lower incidence in a very large group (vaccinated) is more meaningful than a slightly higher rate in a very small group (individuals infected with COVID-19).

    scales of justice
    Your support helps fund this work, and CHD’s related advocacy, education and scientific research.

    Donate Now

    On that basis, Klement and Walach estimated the number of myocarditis cases among all German COVID-19 hospitalizations at 27,467, and among those who were vaccinated at 1.97 million.

    As a result, regardless of myocarditis severity, there were 71.7 times as many myocarditis cases among the vaccinated as among those hospitalized for COVID-19.

    A similar analysis for Switzerland estimated 169,960 cases of myocarditis among vaccinated compared with 8,179 among those hospitalized for COVID-19. Although not as dramatic as the German estimates this still shows a much higher occurrence of heart damage among vaccinated versus hospitalized.

    In a June 2021 paper, Walach, Klement and Dutch data analyst Wouter Aukema concluded that based on 700 adverse reactions, 16 serious side effects and 4.11 deaths for every 100,000 vaccinations, COVID-19 vaccines were released with insufficient safety data.

    The authors said the risk-benefit ratio for mRNA vaccines did not add up because “for three deaths prevented by vaccination we have to accept two inflicted by vaccination.”

    Mueller told The Defender via email:

    “Our study reveals an important lack of prospective safety data concerning COVID-19 vaccines. Given the magnitude of the vaccinated population compared to the much smaller proportion of the population that became infected and developed symptoms, including a small percentage with possible heart damage, our findings should remain qualitatively robust.”

    LEARN MORE ⬇️
    https://childrenshealthdefense.org/defender/covid-study-myocarditis-vaccines/

    Join ➡️ @ShankaraChetty
    🚨 Study Claims COVID Caused More Heart Damage Than Vaccines — Here’s What the Authors Got Wrong Rainer Johannes Klement, Ph.D + Harald Walach reanalyzed data and found that while coronaviruses might cause myocarditis, the COVID-19 vaccines cause at least as much or more. Study Claims COVID Caused More Heart Damage Than Vaccines — Here’s What the Authors Got Wrong A 2023 study admitted that the COVID-19 mRNA vaccines cause myocarditis, but claimed the COVID-19 virus was even more damaging than the vaccine. A recent, more detailed review of their data, however, showed the opposite is likely true. Angelo DePalma, Ph.D. human heart with covid vaccine Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free. Despite the known side effects of mRNA COVID-19 vaccines, some studies (here, here and here) and health websites (here, here and here) argue that whatever vaccination’s adverse outcomes, being unvaccinated is worse. In one such study, Dr. Christian Mueller and his co-authors concluded the COVID-19 virus — not the vaccine — was responsible for more myocarditis, or heart muscle damage, than the vaccine. However, when Rainer Johannes Klement, Ph.D., a physicist at Leopoldina Hospital in Schweinfurt, Germany, and Harald Walach, a clinical psychologist and head of the Change Health Institute in Basel, Switzerland, reanalyzed Mueller’s data they found that while coronaviruses might cause myocarditis, the COVID-19 vaccines cause at least as much or more. The Klement paper appeared in the Feb. 1 edition of The Egyptian Health Journal. Mueller’s study Mueller set out to quantify and compare myocarditis in vaxed versus unvaxed subjects and to explain possible mechanisms. To explore these mechanisms, the researchers tested subjects for antibodies against interleukin-1 receptor antagonist (IL-1RA), the SARS-CoV-2-nucleoprotein, the viral spike protein and 14 inflammatory cytokines. Since none of these measures differed between study groups, the “mechanism” issue was unresolved. To assess myocarditis investigators tested 777 hospital workers (median age 37, 69.5% women) for cardiac troponin T one and three days after they received an mRNA-1273 booster. Cardiologists typically prescribe this test after a suspected heart attack to quantify the extent and duration of heart damage. Of the 40 subjects (5.1%) with elevated troponin on Day 3, 22 (2.8%) were diagnosed with myocarditis, with 20 cases occurring in women and two in men. The researchers reported that among these subjects troponin elevations were mild and temporary and did not involve abnormalities as determined by electrocardiogram. No patients experienced “major adverse cardiac events” within 30 days of receiving the shot. Mueller’s team concluded: COVID-19 associates with a substantially higher risk for myocarditis that [sic] mRNA vaccination … Myocarditis related to COVID-19 infection has shown a higher mortality than myocarditis related to mRNA vaccination. Before the COVID-19 vaccine were [sic] available, the incidence and extent of myocardial injury associated with COVID-19 infection was [sic] much higher than observed in this active surveillance study after booster vaccination. One of the Mueller co-authors had commercial ties to diagnostics companies. Another had previously been compensated by diagnostics and vaccine manufacturers. Mueller had relationships with diagnostics, pharmaceutical and vaccine companies at the time he wrote the paper. Where did Mueller go wrong? One way to measure treatment effects is to compare an outcome, for example, blood pressure, in the same subjects before and after the treatment and report before-and-after results. Although this option was known to medical researchers and available to him, Mueller did not take advantage of it — either because he did not think to measure pre-booster troponin levels or chose not to report them for some reason, perhaps because they did not align with his other results. Instead, his team took an approach that required two well-matched study groups. Although Mueller claimed placebos and controls met this requirement they differed on the feature that mattered most: heart health. Vaccinated subjects with current or recent heart issues were excluded from the study, while all control subjects had just entered the hospital with heart symptoms and were therefore already at greater risk for myocarditis. Klement and Walach found more anomalies in the Mueller paper. RFK Jr. and Brian Hooker Vax-Unvax RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax” Order Now They began their critique by citing three 2021 studies on COVID-19 vaccine-induced myocarditis (here, here and here). All three studies showed myocarditis became a concern shortly after the COVID-19 vaccine introductions. They discussed three papers in some detail: A 2023 German autopsy study on 25 unexpected deaths within 20 days of COVID-19 vaccination identified acute myocarditis as the most probable cause of death in four cases. A 2023 report on myocarditis in 303 non-vaccinated and 700 vaccinated asymptomatic subjects found significantly higher damage in the vaccinated persisting for up to 180 days post-vaccination. One of the first autopsy papers, an Indian-led study based on World Health Organization pharmacovigilance data reported 2.1 times the risk for cardiac arrest, 2.7 times the risk for acute heart attack, 2.6 times the risk for elevated troponin, and 7.3-fold higher levels of D-dimer for COVID-19 vaccinations compared with the use of other medications. These studies strongly suggest that myocarditis became an issue only after the mRNA vaccine rollouts. They contradict Mueller’s statement that the “extent of myocardial injury associated with COVID-19 infection was much higher than observed in this active surveillance study after booster vaccination.” According to Klement and Walach, this statement is wrong for two reasons. First, in addition to the non-equivalence of controls’ and subjects’ heart-health status, Mueller ignored the much larger number of COVID-19-infected, unhospitalized, unvaccinated individuals with (presumably) much lower troponin levels compared with patients entering the hospital with heart symptoms. Second, Klement and Walach argued that the public health impact of myocarditis depends not only on the incidence or rate among study groups but the size of those groups. The significance is that a lower incidence in a very large group (vaccinated) is more meaningful than a slightly higher rate in a very small group (individuals infected with COVID-19). scales of justice Your support helps fund this work, and CHD’s related advocacy, education and scientific research. Donate Now On that basis, Klement and Walach estimated the number of myocarditis cases among all German COVID-19 hospitalizations at 27,467, and among those who were vaccinated at 1.97 million. As a result, regardless of myocarditis severity, there were 71.7 times as many myocarditis cases among the vaccinated as among those hospitalized for COVID-19. A similar analysis for Switzerland estimated 169,960 cases of myocarditis among vaccinated compared with 8,179 among those hospitalized for COVID-19. Although not as dramatic as the German estimates this still shows a much higher occurrence of heart damage among vaccinated versus hospitalized. In a June 2021 paper, Walach, Klement and Dutch data analyst Wouter Aukema concluded that based on 700 adverse reactions, 16 serious side effects and 4.11 deaths for every 100,000 vaccinations, COVID-19 vaccines were released with insufficient safety data. The authors said the risk-benefit ratio for mRNA vaccines did not add up because “for three deaths prevented by vaccination we have to accept two inflicted by vaccination.” Mueller told The Defender via email: “Our study reveals an important lack of prospective safety data concerning COVID-19 vaccines. Given the magnitude of the vaccinated population compared to the much smaller proportion of the population that became infected and developed symptoms, including a small percentage with possible heart damage, our findings should remain qualitatively robust.” LEARN MORE ⬇️ https://childrenshealthdefense.org/defender/covid-study-myocarditis-vaccines/ Join ➡️ @ShankaraChetty
    CHILDRENSHEALTHDEFENSE.ORG
    Study Claims COVID Caused More Heart Damage Than Vaccines — Here’s What the Authors Got Wrong
    A 2023 study admitted that the COVID-19 mRNA vaccines cause myocarditis, but claimed the COVID-19 virus was even more damaging than the vaccine. A recent, more detailed review of their data, however, showed the opposite is likely true.
    Like
    1
    0 Comentários 0 Compartilhamentos 7933 Visualizações
  • Cult Killer
    When a renowned private investigator is murdered, his protege takes on the case. As her investigation unfolds, she is forced into a dangerous alliance with his killer to uncover the town's grisly secrets and bring justice to its v...Watch Full Movie►► https://shorturl.at/ltFMU
    #romance #drama #movie
    Cult Killer When a renowned private investigator is murdered, his protege takes on the case. As her investigation unfolds, she is forced into a dangerous alliance with his killer to uncover the town's grisly secrets and bring justice to its v...Watch Full Movie►► https://shorturl.at/ltFMU #romance #drama #movie
    0 Comentários 0 Compartilhamentos 1430 Visualizações
  • A quartet of Morgan Skelley, Kannon Goodman, Arthur Allison, and Luke Plugge from the University of Florida featured the works of Mike Forbes, Jesse McConnell, Bente Illevold, and Satoshi Yagisawa at The U.S. Army Band 2024 Tuba-Euphonium Workshop. #Florida #UF #GatorMade #GoGators #Quartet #Euphonium #Tuba #TEW2024 #TEW #Music
    A quartet of Morgan Skelley, Kannon Goodman, Arthur Allison, and Luke Plugge from the University of Florida featured the works of Mike Forbes, Jesse McConnell, Bente Illevold, and Satoshi Yagisawa at The U.S. Army Band 2024 Tuba-Euphonium Workshop. #Florida #UF #GatorMade #GoGators #Quartet #Euphonium #Tuba #TEW2024 #TEW #Music
    0 Comentários 0 Compartilhamentos 1820 Visualizações
  • Bonjour à tous,
    Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents.
    --—
    S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après :
    https://markethive.com/christopheleroy/page/christopheleroy
    ------
    à propos de mon profil bio :
    https://markethive.com/christopheleroy
    ------
    Markethive, explications pour devenir Entrepreneur en français :
    https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais
    ------
    Markethive, explanations to become Entrepreneur (en) :
    https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur
    ------
    Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow
    ------
    Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive :
    https://www.youtube.com/watch?v=lQc8ANrPzDI
    ------
    Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire.
    NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels.
    ------
    #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Bonjour à tous, Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents. --— S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après : https://markethive.com/christopheleroy/page/christopheleroy ------ à propos de mon profil bio : https://markethive.com/christopheleroy ------ Markethive, explications pour devenir Entrepreneur en français : https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais ------ Markethive, explanations to become Entrepreneur (en) : https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur ------ Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow ------ Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive : https://www.youtube.com/watch?v=lQc8ANrPzDI ------ Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire. NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels. ------ #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Wow
    1
    0 Comentários 0 Compartilhamentos 9716 Visualizações
  • Bonjour à tous,
    Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents.
    --—
    S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après :
    https://markethive.com/christopheleroy/page/christopheleroy
    ------
    à propos de mon profil bio :
    https://markethive.com/christopheleroy
    ------
    Markethive, explications pour devenir Entrepreneur en français :
    https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais
    ------
    Markethive, explanations to become Entrepreneur (en) :
    https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur
    ------
    Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow
    ------
    Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive :
    https://www.youtube.com/watch?v=lQc8ANrPzDI
    ------
    Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire.
    NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels.
    ------
    #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Bonjour à tous, Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents. --— S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après : https://markethive.com/christopheleroy/page/christopheleroy ------ à propos de mon profil bio : https://markethive.com/christopheleroy ------ Markethive, explications pour devenir Entrepreneur en français : https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais ------ Markethive, explanations to become Entrepreneur (en) : https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur ------ Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow ------ Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive : https://www.youtube.com/watch?v=lQc8ANrPzDI ------ Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire. NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels. ------ #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Love
    2
    0 Comentários 0 Compartilhamentos 9209 Visualizações
  • Bonjour à tous,
    Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents.
    --—
    S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après :
    https://markethive.com/christopheleroy/page/christopheleroy
    ------
    à propos de mon profil bio :
    https://markethive.com/christopheleroy
    ------
    Markethive, explications pour devenir Entrepreneur en français :
    https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais
    ------
    Markethive, explanations to become Entrepreneur (en) :
    https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur
    ------
    Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow
    ------
    Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive :
    https://www.youtube.com/watch?v=lQc8ANrPzDI
    ------
    Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire.
    NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels.
    ------
    #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Bonjour à tous, Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents. --— S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après : https://markethive.com/christopheleroy/page/christopheleroy ------ à propos de mon profil bio : https://markethive.com/christopheleroy ------ Markethive, explications pour devenir Entrepreneur en français : https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais ------ Markethive, explanations to become Entrepreneur (en) : https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur ------ Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow ------ Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive : https://www.youtube.com/watch?v=lQc8ANrPzDI ------ Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire. NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels. ------ #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Love
    1
    0 Comentários 0 Compartilhamentos 8774 Visualizações
  • Bonjour à tous,
    Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents.
    --—
    S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après :
    https://markethive.com/christopheleroy/page/christopheleroy
    ------
    à propos de mon profil bio :
    https://markethive.com/christopheleroy
    ------
    Markethive, explications pour devenir Entrepreneur en français :
    https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais
    ------
    Markethive, explanations to become Entrepreneur (en) :
    https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur
    ------
    Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow
    ------
    Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive :
    https://www.youtube.com/watch?v=lQc8ANrPzDI
    ------
    Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire.
    NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels.
    ------
    #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Bonjour à tous, Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents. --— S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après : https://markethive.com/christopheleroy/page/christopheleroy ------ à propos de mon profil bio : https://markethive.com/christopheleroy ------ Markethive, explications pour devenir Entrepreneur en français : https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais ------ Markethive, explanations to become Entrepreneur (en) : https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur ------ Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow ------ Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive : https://www.youtube.com/watch?v=lQc8ANrPzDI ------ Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire. NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels. ------ #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Love
    1
    0 Comentários 0 Compartilhamentos 8419 Visualizações
  • Bonjour à tous,
    Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents.
    --—
    S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après :
    https://markethive.com/christopheleroy/page/christopheleroy
    ------
    à propos de mon profil bio :
    https://markethive.com/christopheleroy
    ------
    Markethive, explications pour devenir Entrepreneur en français :
    https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais
    ------
    Markethive, explanations to become Entrepreneur (en) :
    https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur
    ------
    Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow
    ------
    Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive :
    https://www.youtube.com/watch?v=lQc8ANrPzDI
    ------
    Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire.
    NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels.
    ------
    #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Bonjour à tous, Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents. --— S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après : https://markethive.com/christopheleroy/page/christopheleroy ------ à propos de mon profil bio : https://markethive.com/christopheleroy ------ Markethive, explications pour devenir Entrepreneur en français : https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais ------ Markethive, explanations to become Entrepreneur (en) : https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur ------ Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow ------ Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive : https://www.youtube.com/watch?v=lQc8ANrPzDI ------ Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire. NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels. ------ #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Love
    1
    0 Comentários 0 Compartilhamentos 8164 Visualizações
  • The Truth About HPV Vaccination, Part 3: Can It Prevent Cervical Cancer?
    There are no valid studies showing the vaccine for the human papillomavirus, or HPV, prevents cervical cancer. However, there are studies suggesting the vaccine could increase the risk of cancer.

    The Epoch Times

    Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.

    By Dr. Yuhong Dong

    Editor’s Note: This third installment in a multi-part series about the human papillomavirus, or HPV, vaccine examines studies that link the vaccines to increased risk of serious neurological and autoimmune disorders. Read Part 1 here and Part 2 here.

    In part 1 and part 2 of this series, we discussed the human papillomavirus (HPV) vaccine and its links to ovarian insufficiency and autoimmune disease.

    In part 3, we turn to questions regarding the effectiveness of the vaccine to prevent cervical cancer, and the limitations of relevant clinical trials to detect such a type of effect.

    Summary of key facts

    There are multiple obstacles in designing a valid clinical trial to prove the HPV vaccine could prevent cervical cancer, e.g. long lead time, lack of adequate informed consent, complexity between HPV infection and cervical cancer and the negative impact of girls’ sexual behavior, which may worsen the risks of cervical cancer.
    Most of the HPV’s interventional clinical trials have too short a follow-up time to draw a concrete conclusion.
    In a large Swedish observational trial, which is treated as the most convincing study to prove the HPV vaccine’s effects on cervical cancer, a few confounding factors were not adequately balanced between the HPV vaccination group versus the unvaccinated group.
    The National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER) data and another U.S. study found the HPV vaccine has no effects in reducing cancer rates.
    Two other registry-based studies in Australia and the U.K. suggest that HPV vaccination is associated with increased cervical cancer rates in certain age groups.
    Long lead time from HPV infection to cervical cancer

    Typically, there is a long period from HPV infection to cervical epithelium abnormalities, then cervical cancer.

    HPV infections usually last 12–18 months and are eventually cleared by the immune system.

    Fewer than 10% of HPV infections are persistent.

    There are two types of precancerous cervical lesions, low-grade or high-grade. Low-grade cervical neoplasia grade 1 (CIN1) is usually transient and resolves naturally within one to two years.

    Only a few persistent infections progress to the clinically meaningful high-grade, CIN2 or 3. Meanwhile, the median time from CIN2/3 to transition to cancer is estimated to be 23.5 years.

    Among those with weakened immune systems, HPV-related cancer might progress more quickly.

    In a review of the natural history of HPV infection, the complex pathway from infection to cancer is elucidated, including what is known (purple boxes) and where uncertainty remains (blue boxes).



    Difficulty running clinical trials for the HPV vaccine

    Because of the long lead time from HPV infection to cervical cancer, a prospective, randomized controlled trial is not easily designed and feasibly implemented.

    Lack of long-term follow-up is a common issue for most clinical trials to prove the HPV vaccine’s effectiveness in preventing cervical cancer.

    For example, a 2007 study found that Gardasil was effective in reducing HPV-associated cervical precancerous lesions rate by 20%.

    This study followed their subjects for only an average of three years after administration of the first dose.

    Furthermore, due to the complex uncertainties in the natural history between HPV infection and cervical cancer, it is not easy to claim the effectiveness of the HPV vaccine.

    A randomized trial is designed to balance the two groups — vaccine and placebo — so that any unmeasured confounding variables which might influence the outcome of the trial are distributed evenly.

    However, if the treatment group knows they got the vaccine, might their behaviors change? Might they be less risk-averse, thinking they have some protection?

    For example, girls might think they are vaccinated and “protected” from cervical cancer and may tend to initiate sexual intercourse at a younger age or engage in sexual activities with more partners.

    However, sexual intercourse at a young age, multiple sexual partners and oral contraceptive use are associated with an increased risk of cervical cancer in women.

    In other words, HPV vaccination may offer some protection if offered before sexual activity is initiated, but it may also be associated with increased behavioral risk factors.

    Whether the benefits of vaccination outweigh any risks is therefore a multifactorial question deserving of careful longitudinal study.

    RFK Jr. and Brian Hooker Vax-Unvax
    RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax”

    Order Now

    Systemic analysis of 12 clinical trials on HPV vaccine efficacy

    In 2020, a Queen Mary University study led by Dr. Claire Rees reviewed 12 randomized clinical trials for Cervarix and Gardasil. The investigators found that the trials did not include populations representative of the vaccination target groups, and the trial design may have overstated vaccine efficacy.

    For example, one trial design generated evidence that the vaccine prevents CIN1. But this is not meaningful because these lesions usually resolve on their own.

    Furthermore, the study accessed efficacy against low-grade precancerous lesions. But this is not necessarily suggestive of efficacy against the more serious but much less frequent high-grade lesions.

    Finally, the cytology screenings were done every six to 12 months instead of every 36 months (normal screening interval), meaning the efficacy of the vaccine may have been overestimated, as low-grade lesions could go away spontaneously.

    All this is to say the HPV vaccine may be effective at preventing more serious lesions which lead to cervical cancer, but it is hard to know because of these poorly designed trials.

    Nothing is conclusive without a larger trial powered to detect a difference in rates of more serious cervical changes according to the typical screening schedule. However, such a trial has not yet been performed.

    Swedish nationwide health registry study

    A nationwide Swedish health registry-based study followed 1,672,983 women for 12 years to assess the association between HPV vaccination and the risk of cervical cancer.

    In this study, the cumulative incidence of cervical cancer was 47 cases per 100,000 women vaccinated and 94 per 100,000 unvaccinated, suggesting that HPV4 vaccination was associated with a reduced risk of 49 to 63% of invasive cervical cancer at the population level.

    Even though the results are positive, the study researchers raised a few concerns themselves.

    First, HPV-vaccinated women could have been generally healthier than unvaccinated women. This is known as “healthy volunteer bias.”

    Second, a mother’s history of cervical cancer might be associated with both vaccination uptake and underlying risk of cervical cancer as well as screening rates.

    Third, lifestyle and health factors such as smoking, sexual intercourse at a young age, multiple sexual partners, oral contraceptive use and obesity are reportedly associated with the risk of cervical cancer.

    These factors have not been thoroughly analyzed by this study and could have contributed to the data.

    Furthermore, parental education level and annual household income level may be interconnected with lifestyle factors such as smoking status.

    Strengths of this study include its size, duration and outcome of interest being invasive cancer, not low-grade lesions. However, it is impossible to exclude the relationship between lifestyle factors, vaccination uptake and cervical cancer.

    Only a randomized controlled trial (RCT) could balance the two groups on these unmeasured — but related — risk factors.

    However even if the risk factors (sexual behaviors) are fully balanced at baseline with an RCT, it is hard to keep them still balanced during the whole study course after HPV vaccination.

    No association found in a U.S. database

    Meanwhile, researchers found no association between vaccination and cancer mortality in the U.S.

    According to the National Cancer Institute’s SEER program, the incidence of deaths from cervical cancer before Gardasil’s introduction in the U.S. had been steadily declining for years and, in 2006, was 2.4 per 100,000 women.

    The data from 2016–2020 is 2.2 per 100,000 women — essentially unchanged.

    In a cross-sectional study using a nationally representative sample of U.S. adults aged 20–59 years, among 9,891 participants, the researchers did not find an association between HPV vaccination and HPV-related cancers.

    Increase in cervical cancer after HPV vaccine rollout: Australia

    In Australia, government data similarly reveal an increase in cervical cancer rates in certain age groups of women following the implementation of the Gardasil vaccine.

    Thirteen years after Gardasil was recommended for teenagers and young adults, there has been a 30% increase in 30- to 34-year-old women (4.9 cases/100,000 compared to 6.6 cases/100,000 in 2020) being diagnosed with cervical cancer.

    Even though the rates decreased in other age groups, the abnormal increase in the 30–34 age group needs an explanation.



    Several factors should be considered.

    First, this database does not tell the stage of cancer. More cancer diagnosed at an early stage may result in a cancer-rate increase.

    Second, decreasing cancer rates could be caused by declines in screening rates, perhaps due to the pandemic and/or a reluctance to get tested.

    Third, Australia has an increasing proportion of immigrants from South Asia, and these cultural factors may influence the cervical cancer-screening rate.

    A study of South Asian women living in Australia found that almost half had never had a previous screening test.

    Cervical cancer rates rise after HPV vaccination in the UK

    In the U.K., HPV vaccination was introduced in 2008 for girls aged 12–13 with catch-up for those aged 14–18. Many expected cervical cancer rates in women aged 20–24 to fall by 2014 as the vaccinated cohorts entered their 20s.

    However, in 2016 national statistics showed a worrying and substantial 70% increase in the rate of cervical cancer at ages 20 to 24 (i.e. from 2.7 in 2012 to 4.6 per 100,000 in 2014).

    While the author would consider it to be too early to draw conclusions regarding vaccine efficacy in protecting against cancer, this merits further study.

    Accordingly, an analysis was conducted in the U.K. in 2018 in response to public interest regarding this increase in cervical cancer.

    Researchers from Queen Mary University and King’s College London found that it was attributable to an increase in the proportion of women first screened at age 24.5 years.

    The increase was limited to stage I cervical cancer. But there was no evidence of a lack of screening leading to increasing rates.

    While the researchers considered it too early to conclude vaccine efficacy in protecting against cancer, these findings merit further study.

    Could HPV vaccines make HPV infections worse?

    Besides the vaccine’s unclear effectiveness in cancer prevention, studies further suggest the suppression of the HPV strains targeted by the vaccine may induce more virulent strains.

    For example, a 2015 study found that vaccinated young adult women had a higher prevalence of high-risk HPV types other than types 16 and 18, putting them at risk for more aggressive cervical and other HPV-related cancers.

    Reprinted with permission from The Epoch Times. Dr. Yuhong Dong, a medical doctor who also holds a doctorate in infectious diseases in China, is the chief scientific officer and co-founder of a Swiss biotech company and former senior medical scientific expert for antiviral drug development at Novartis Pharma in Switzerland.

    If you or your child suffered harm after receiving the Gardasil HPV vaccine, you may have a legal claim. Please visit Wisner Baum for a free case evaluation. Click here to watch a Gardasil litigation update interview with Wisner Baum Senior Partner Bijan Esfandiari.

    https://childrenshealthdefense.org/defender/truth-hpv-vaccine-part-3-et/


    https://donshafi911.blogspot.com/2024/01/the-truth-about-hpv-vaccination-part-3.html
    The Truth About HPV Vaccination, Part 3: Can It Prevent Cervical Cancer? There are no valid studies showing the vaccine for the human papillomavirus, or HPV, prevents cervical cancer. However, there are studies suggesting the vaccine could increase the risk of cancer. The Epoch Times Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free. By Dr. Yuhong Dong Editor’s Note: This third installment in a multi-part series about the human papillomavirus, or HPV, vaccine examines studies that link the vaccines to increased risk of serious neurological and autoimmune disorders. Read Part 1 here and Part 2 here. In part 1 and part 2 of this series, we discussed the human papillomavirus (HPV) vaccine and its links to ovarian insufficiency and autoimmune disease. In part 3, we turn to questions regarding the effectiveness of the vaccine to prevent cervical cancer, and the limitations of relevant clinical trials to detect such a type of effect. Summary of key facts There are multiple obstacles in designing a valid clinical trial to prove the HPV vaccine could prevent cervical cancer, e.g. long lead time, lack of adequate informed consent, complexity between HPV infection and cervical cancer and the negative impact of girls’ sexual behavior, which may worsen the risks of cervical cancer. Most of the HPV’s interventional clinical trials have too short a follow-up time to draw a concrete conclusion. In a large Swedish observational trial, which is treated as the most convincing study to prove the HPV vaccine’s effects on cervical cancer, a few confounding factors were not adequately balanced between the HPV vaccination group versus the unvaccinated group. The National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER) data and another U.S. study found the HPV vaccine has no effects in reducing cancer rates. Two other registry-based studies in Australia and the U.K. suggest that HPV vaccination is associated with increased cervical cancer rates in certain age groups. Long lead time from HPV infection to cervical cancer Typically, there is a long period from HPV infection to cervical epithelium abnormalities, then cervical cancer. HPV infections usually last 12–18 months and are eventually cleared by the immune system. Fewer than 10% of HPV infections are persistent. There are two types of precancerous cervical lesions, low-grade or high-grade. Low-grade cervical neoplasia grade 1 (CIN1) is usually transient and resolves naturally within one to two years. Only a few persistent infections progress to the clinically meaningful high-grade, CIN2 or 3. Meanwhile, the median time from CIN2/3 to transition to cancer is estimated to be 23.5 years. Among those with weakened immune systems, HPV-related cancer might progress more quickly. In a review of the natural history of HPV infection, the complex pathway from infection to cancer is elucidated, including what is known (purple boxes) and where uncertainty remains (blue boxes). Difficulty running clinical trials for the HPV vaccine Because of the long lead time from HPV infection to cervical cancer, a prospective, randomized controlled trial is not easily designed and feasibly implemented. Lack of long-term follow-up is a common issue for most clinical trials to prove the HPV vaccine’s effectiveness in preventing cervical cancer. For example, a 2007 study found that Gardasil was effective in reducing HPV-associated cervical precancerous lesions rate by 20%. This study followed their subjects for only an average of three years after administration of the first dose. Furthermore, due to the complex uncertainties in the natural history between HPV infection and cervical cancer, it is not easy to claim the effectiveness of the HPV vaccine. A randomized trial is designed to balance the two groups — vaccine and placebo — so that any unmeasured confounding variables which might influence the outcome of the trial are distributed evenly. However, if the treatment group knows they got the vaccine, might their behaviors change? Might they be less risk-averse, thinking they have some protection? For example, girls might think they are vaccinated and “protected” from cervical cancer and may tend to initiate sexual intercourse at a younger age or engage in sexual activities with more partners. However, sexual intercourse at a young age, multiple sexual partners and oral contraceptive use are associated with an increased risk of cervical cancer in women. In other words, HPV vaccination may offer some protection if offered before sexual activity is initiated, but it may also be associated with increased behavioral risk factors. Whether the benefits of vaccination outweigh any risks is therefore a multifactorial question deserving of careful longitudinal study. RFK Jr. and Brian Hooker Vax-Unvax RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax” Order Now Systemic analysis of 12 clinical trials on HPV vaccine efficacy In 2020, a Queen Mary University study led by Dr. Claire Rees reviewed 12 randomized clinical trials for Cervarix and Gardasil. The investigators found that the trials did not include populations representative of the vaccination target groups, and the trial design may have overstated vaccine efficacy. For example, one trial design generated evidence that the vaccine prevents CIN1. But this is not meaningful because these lesions usually resolve on their own. Furthermore, the study accessed efficacy against low-grade precancerous lesions. But this is not necessarily suggestive of efficacy against the more serious but much less frequent high-grade lesions. Finally, the cytology screenings were done every six to 12 months instead of every 36 months (normal screening interval), meaning the efficacy of the vaccine may have been overestimated, as low-grade lesions could go away spontaneously. All this is to say the HPV vaccine may be effective at preventing more serious lesions which lead to cervical cancer, but it is hard to know because of these poorly designed trials. Nothing is conclusive without a larger trial powered to detect a difference in rates of more serious cervical changes according to the typical screening schedule. However, such a trial has not yet been performed. Swedish nationwide health registry study A nationwide Swedish health registry-based study followed 1,672,983 women for 12 years to assess the association between HPV vaccination and the risk of cervical cancer. In this study, the cumulative incidence of cervical cancer was 47 cases per 100,000 women vaccinated and 94 per 100,000 unvaccinated, suggesting that HPV4 vaccination was associated with a reduced risk of 49 to 63% of invasive cervical cancer at the population level. Even though the results are positive, the study researchers raised a few concerns themselves. First, HPV-vaccinated women could have been generally healthier than unvaccinated women. This is known as “healthy volunteer bias.” Second, a mother’s history of cervical cancer might be associated with both vaccination uptake and underlying risk of cervical cancer as well as screening rates. Third, lifestyle and health factors such as smoking, sexual intercourse at a young age, multiple sexual partners, oral contraceptive use and obesity are reportedly associated with the risk of cervical cancer. These factors have not been thoroughly analyzed by this study and could have contributed to the data. Furthermore, parental education level and annual household income level may be interconnected with lifestyle factors such as smoking status. Strengths of this study include its size, duration and outcome of interest being invasive cancer, not low-grade lesions. However, it is impossible to exclude the relationship between lifestyle factors, vaccination uptake and cervical cancer. Only a randomized controlled trial (RCT) could balance the two groups on these unmeasured — but related — risk factors. However even if the risk factors (sexual behaviors) are fully balanced at baseline with an RCT, it is hard to keep them still balanced during the whole study course after HPV vaccination. No association found in a U.S. database Meanwhile, researchers found no association between vaccination and cancer mortality in the U.S. According to the National Cancer Institute’s SEER program, the incidence of deaths from cervical cancer before Gardasil’s introduction in the U.S. had been steadily declining for years and, in 2006, was 2.4 per 100,000 women. The data from 2016–2020 is 2.2 per 100,000 women — essentially unchanged. In a cross-sectional study using a nationally representative sample of U.S. adults aged 20–59 years, among 9,891 participants, the researchers did not find an association between HPV vaccination and HPV-related cancers. Increase in cervical cancer after HPV vaccine rollout: Australia In Australia, government data similarly reveal an increase in cervical cancer rates in certain age groups of women following the implementation of the Gardasil vaccine. Thirteen years after Gardasil was recommended for teenagers and young adults, there has been a 30% increase in 30- to 34-year-old women (4.9 cases/100,000 compared to 6.6 cases/100,000 in 2020) being diagnosed with cervical cancer. Even though the rates decreased in other age groups, the abnormal increase in the 30–34 age group needs an explanation. Several factors should be considered. First, this database does not tell the stage of cancer. More cancer diagnosed at an early stage may result in a cancer-rate increase. Second, decreasing cancer rates could be caused by declines in screening rates, perhaps due to the pandemic and/or a reluctance to get tested. Third, Australia has an increasing proportion of immigrants from South Asia, and these cultural factors may influence the cervical cancer-screening rate. A study of South Asian women living in Australia found that almost half had never had a previous screening test. Cervical cancer rates rise after HPV vaccination in the UK In the U.K., HPV vaccination was introduced in 2008 for girls aged 12–13 with catch-up for those aged 14–18. Many expected cervical cancer rates in women aged 20–24 to fall by 2014 as the vaccinated cohorts entered their 20s. However, in 2016 national statistics showed a worrying and substantial 70% increase in the rate of cervical cancer at ages 20 to 24 (i.e. from 2.7 in 2012 to 4.6 per 100,000 in 2014). While the author would consider it to be too early to draw conclusions regarding vaccine efficacy in protecting against cancer, this merits further study. Accordingly, an analysis was conducted in the U.K. in 2018 in response to public interest regarding this increase in cervical cancer. Researchers from Queen Mary University and King’s College London found that it was attributable to an increase in the proportion of women first screened at age 24.5 years. The increase was limited to stage I cervical cancer. But there was no evidence of a lack of screening leading to increasing rates. While the researchers considered it too early to conclude vaccine efficacy in protecting against cancer, these findings merit further study. Could HPV vaccines make HPV infections worse? Besides the vaccine’s unclear effectiveness in cancer prevention, studies further suggest the suppression of the HPV strains targeted by the vaccine may induce more virulent strains. For example, a 2015 study found that vaccinated young adult women had a higher prevalence of high-risk HPV types other than types 16 and 18, putting them at risk for more aggressive cervical and other HPV-related cancers. Reprinted with permission from The Epoch Times. Dr. Yuhong Dong, a medical doctor who also holds a doctorate in infectious diseases in China, is the chief scientific officer and co-founder of a Swiss biotech company and former senior medical scientific expert for antiviral drug development at Novartis Pharma in Switzerland. If you or your child suffered harm after receiving the Gardasil HPV vaccine, you may have a legal claim. Please visit Wisner Baum for a free case evaluation. Click here to watch a Gardasil litigation update interview with Wisner Baum Senior Partner Bijan Esfandiari. https://childrenshealthdefense.org/defender/truth-hpv-vaccine-part-3-et/ https://donshafi911.blogspot.com/2024/01/the-truth-about-hpv-vaccination-part-3.html
    CHILDRENSHEALTHDEFENSE.ORG
    The Truth About HPV Vaccination, Part 3: Can It Prevent Cervical Cancer?
    There are no valid studies showing the vaccine for the human papillomavirus, or HPV, prevents cervical cancer. However, there are studies suggesting the vaccine could increase the risk of cancer.
    Like
    1
    0 Comentários 0 Compartilhamentos 12520 Visualizações
  • The Truth About HPV Vaccination, Part 2: Studies Link the Vaccines to Neurological, Autoimmune Disorders
    Researchers who looked closely into the Gardasil HPV vaccine concluded the risks from the vaccine seem to significantly outweigh the as-yet-unproven long-term benefits.

    The Epoch Times

    Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.

    By Dr. Yuhong Dong

    Editor’s Note: This second installment in a multi-part series about the human papillomavirus, or HPV, vaccine examines studies that link the vaccines to increased risk of serious neurological and autoimmune disorders. Read Part 1 here.

    Summary of key facts

    A Danish review of 79,102 female and 16,568 male subjects, found human papillomavirus (HPV) vaccines had significantly increased rates of serious nervous system disorders. Postural orthostatic tachycardia syndrome (POTS) and complex regional pain syndrome were judged “definitely associated” with the HPV vaccine.
    A large Danish and Swedish study including nearly 300,000 girls found a significant association between the HPV vaccine and increased rates of Bechet’s syndrome (rate ratio 3.37), Raynaud’s disease (1.67) and type 1 diabetes (1.29).
    A large study including 3 million Danish and Swedish women aged 18 to 44, identified seven adverse events with statistically significant increased risks following HPV vaccination: Hashimoto’s thyroiditis, celiac disease, lupus erythematosus, pemphigus vulgaris, Addison’s disease, Raynaud’s disease and encephalitis, myelitis, or encephalomyelitis.
    A 2017 French study of over 2.2 million young girls found evidence of a 3.78-fold increased risk of Guillain-Barré syndrome (GBS). A 2011 U.S. study found nearly a two-and-a-half to 10 times greater risk of acquiring GBS within six weeks post-Gardasil vaccination.
    While the underlying mechanisms causing these autoimmune reactions are not yet fully understood, some researchers speculate that the sizable overlap in protein sequences between the HPV and the human genome may cause the immune system to attack itself. Others are concerned that the adjuvants (such as aluminum) used to attract the attention of the immune system may be causing harm.
    Neurological and autoimmune disorders

    Danish review found increased nervous system disorder

    In 2020, a group of Danish scientists conducted a systematic review of the overall benefits and harms of HPV vaccines.

    Twenty-four eligible randomized controlled clinical studies were obtained, with a total of 95,670 participants, mostly women, and 49 months mean weighted follow-up.

    Almost all controls were given an active comparator vaccine (typically a hepatitis vaccine with a comparable aluminum-based adjuvant).

    Given that the adjuvant is highly immunogenic by design (it is meant to grab the attention of the immune system), this trial design makes it difficult to detect an excess risk with the HPV vaccines.

    Without true controls (such as a saline placebo), the real risks of HPV vaccination cannot be accurately assessed.

    In the vaccine group, 367 cancers were detected, compared to 490 in the comparator group.

    Younger participants (15 to 29) seemed to benefit more from the vaccine concerning preventing moderate HPV-related intraepithelial neoplasia compared to older participants (ages 21 to 72). Younger participants also had fewer fatal harms.

    Even though the studies were flawed in their design, at four years post-vaccination, those who had received the HPV vaccines had significantly increased rates of serious nervous system disorders: 49%, as well as general harms totaling 7%.

    The serious harms that were judged “definitely associated” with HPV vaccines were postural orthostatic tachycardia syndrome and complex regional pain syndrome. POTS had a nearly twofold increase in the vaccinated group.

    By July 2017, only two-thirds of the results from HPV vaccine trials had been published, and only about half the results had been posted, due to manuscript length limitations, reporting bias and confounding journal articles offering a limited view of trial outcomes.

    This Danish systematic review compiled data from all the HPV trials to offer a summary of the evidence thus far.

    Nevertheless, the investigators acknowledged that despite three years of work, the limitations of their analysis remained. These included reporting bias, incomplete reporting, data fragmentation and limited trial follow-up.

    These investigators similarly note that the trials were powered to assess the benefits of HPV vaccination, not rare harms. The degree to which benefits outweigh risks is therefore unknown.

    They concluded that future research should carefully evaluate the harms following Gardasil 9 compared to Gardasil because the former contains more than double the virus proteins and aluminum-containing adjuvant than the same dose of Gardasil.

    RFK Jr. and Brian Hooker Vax-Unvax
    RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax”

    Order Now

    Large studies reveal autoimmune events

    In 2009, the HPV4 vaccine was integrated into the Danish childhood vaccination program. Since then, two large cohort studies on the HPV4 vaccine adverse events have been carried out using the hospital-based healthcare registries of Denmark and Sweden.

    The first study in Denmark and Sweden included 296,826 girls aged 10 to 17 who received a total of 696,420 HPV4 vaccine doses.

    The scientists evaluated rate ratios for autoimmune events and found no significant association for 20 out of 23 events.

    They found a significant association between the HPV4 vaccine and Bechet’s syndrome (rate ratio 3.37), Raynaud’s disease (1.67) and type 1 diabetes (1.29).

    But after further review, they concluded that there was insufficient evidence for a causal association, because of the weakness of the signal and the lack of an underlying mechanism to explain biological plausibility.

    In a second large cohort study, the same team expanded their research to more than 3 million Danish and Swedish adult women aged 18 to 44.

    The authors identified seven adverse events with statistically significant increased risks following HPV4 vaccination: Hashimoto’s thyroiditis, celiac disease, lupus erythematosus, pemphigus vulgaris, Addison’s disease, Raynaud’s disease and encephalitis, myelitis or encephalomyelitis.

    After sensitivity analyses, the association between HPV4 vaccination and celiac disease was the most robust finding.

    Celiac disease is a condition where a person’s immune system attacks the body’s own gut after eating gluten.

    As the graph below shows, the scientists used two risk periods after HPV4 vaccination: the first 180 days and after.

    1 time since first dose HPV4 vaccine coeliac cases
    Time since the first dose of the HPV4 vaccine for vaccinated coeliac cases in a cohort of Danish and Swedish women. Credit: Journal of Internal Medicine
    The authors noted that the observed 56% increased risk of celiac disease “was strong, and the increase was strikingly similar in both risk periods after vaccination.”

    Celiac disease is underdiagnosed in Denmark.

    So one possible explanation is that vaccination visits allow a chance for this and other conditions to be diagnosed and explored.

    This explanation suggests that the association between the HPV vaccine and autoimmune disorders may be coincidental.

    However, given the lack of any real control groups in these studies, as well as the growing body of scientific literature from countries around the world showing problems with the HPV vaccine, dismissing these safety signals as coincidence seems short-sighted.

    Large French study and U.S. VAERS study identify risks of Guillain-Barré Syndrome

    The concern about autoimmune disease adverse events has contributed to low HPV vaccination uptake in France.

    A 2017 study of over 2.2 million young girls in France found troubling evidence of a link with Guillain-Barré syndrome. GBS is a condition that arises when our own antibodies attack the nerves.

    The incidence of GBS was found to be 1.4 per 100,000 person-years among the vaccinated girls compared to 0.4 per 100,000 among the unvaccinated, resulting in an increased risk of GBS of more than 200%.

    The association appeared to be “particularly marked in the first months following vaccination.”

    This finding is corroborated by the pattern of adverse reactions reported worldwide. Data from a large number of case reports document similar serious adverse events associated with Gardasil administration, with nervous system disorders of autoimmune origin being the most frequently reported.

    A 2011 U.S. study found that the estimated weekly reporting rate of post-Gardasil GBS within the first six weeks (6.6 per 10,000,000) was higher than in the general population, and higher than post-Menactra and post-influenza vaccinations.

    In particular, there was nearly a two-and-a-half to 10 times greater risk of acquiring GBS within six weeks after vaccination, compared to the general population.

    Additionally, the study found Gardasil vaccination was associated with approximately eight-and-a-half times more emergency department visits, 12.5 times more hospitalizations, 10 times more life-threatening events and 26.5 times more disability than the Menactra vaccination.

    Plausible mechanisms of harm

    Despite the conflicting data in the scientific literature to date, it is clear that the HPV vaccines can cause autoimmune disorders in susceptible people. But how?

    Autoimmunity has been reported as a complication of natural infection as well as virus vaccination. This phenomenon has been observed with many viruses, including the Epstein-Barr virus, COVID-19 and HPV.

    According to a 2019 study, the HPV vaccine contains epitopes — portions of the virus proteins — that overlap with the human proteins.

    This means that if we develop antibodies to those viruses, we may also generate autoantibodies to our own cells, which is the root cause of autoimmune dysfunction.

    The study showed that most of the immunoreactive HPV L1 epi­topes are overlapping peptides present in human proteins.

    The authors explained that this “unexpected enormous size of the peptide overlap between the HPV epitopes and human proteins” is relevant, and may be why a wide variety of autoimmune diseases have been reported post-HPV vaccination, including ovarian failure, systemic lupus erythematosus, breast cancer and sudden death, among others.

    Why some people develop these conditions and others do not is unclear.

    The authors suggest that vaccines should target the few peptides that do not overlap with human proteins, but which do overlap with the other HPVs.

    Despite this overlap and the potential for causing autoimmune disease, medical doctors usually ignore or dismiss the connection. We are told that these diseases are rare.

    The human body has something called immune tolerance. This protects a person’s immune system against attacking itself. Therefore, HPV infection is also “immune tolerated,” which means it lays dormant for some time until it becomes cancerous.

    HPV vaccination was actually designed with this immune tolerance in mind.

    Given the human body’s built-in defenses against autoimmune conditions, vaccinology requires an immunogenic catalyst to get the body’s attention. This is the job of an adjuvant.

    An adjuvant is an ingredient used in a vaccine that the body recognizes as foreign. It is added to vaccines so that the body will mount a stronger immune response.

    The idea is that in attacking the adjuvant, the body will also recognize other vaccine ingredients (in this case, purified HPV proteins).

    In addition, the antigen dose is much higher than in natural infections and the capsids in the vaccine are directly exposed to systemic immune responses as opposed to the virus staying relatively hidden within the natural barrier of the skin following infection.

    The vaccine was well-designed to trigger an immune response, but this advantage may come at a cost: Generating antibodies to HPV proteins through vaccination could, theoretically, set the stage for an autoimmune attack.

    Link between HPV-vaccine-associated nervous system dysfunction and autoimmunity

    A December 2022 Danish and German study was designed to elucidate a possible mechanism of harm.

    The lead author, Dr. Jesper Mehlsen, a specialist in treating autoimmune conditions, noted that the HPV major capsid L1s antigen resembles human autonomic nerve receptors, including G-protein coupled receptors (GPCR).

    According to the researchers, in the past several years, case series of suspected vaccination side effects have pointed to three disease entities: POTS, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and complex regional pain syndrome. These syndromes may be associated with neuroendocrine GPCR antibodies.

    From 2011 to 2018, researchers saw 845 patients (839 females, six males) with suspected side effects following the HPV4 vaccine. The control group included vaccinated people without side effects.

    Moderate to severe fatigue was recorded in 83.3% of the patients but in none of the controls.

    A high prevalence of symptoms, such as dizziness (91%), heart palpitations (71%), nausea (80%) and hyperactive bladder suggested that the patients were experiencing some kind of autonomic dysfunction.

    Autonomic dysfunction occurs when the part of the nervous system that controls well-being and balance does not function properly.

    2 most frequent symptoms hpv vaccine
    Most frequent symptoms reported by 612 patients in Denmark. Credit: Journal of Autoimmunity
    Twenty-four percent higher antinuclear antibodies (ANA, a common type of autoantibodies) were found in patients, suggesting possible autoimmunity.

    3 antinuclear antibodies HPV vaccines
    A larger proportion of the symptomatic patients were found with a common type of autoantibodies compared to healthy controls. Credit: Journal of Autoimmunity
    Antibodies against the adrenergic ß-2-receptor and muscarinic M-2 receptors were also found significantly higher in patients.

    Many of the symptoms, including immune activation and autonomic dysregulation, could be mediated or aggravated by dysregulated autoantibodies against adrenergic receptors and impaired peripheral adrenergic function.

    The authors suggested that girls and women with probable side effects of HPV vaccination have symptoms and biological markers compatible with an autoimmune disease closely resembling that seen in ME/CFS.

    Interestingly, people who already had HPV infections at some point appeared to be at greater risk for adverse events following vaccination.

    The authors noted that “prior disease may precondition some individuals for vaccine-related adverse events.”

    They also noted that some of the adverse events resembled long-COVID symptoms.

    Universal HPV vaccination called into question

    Academic researcher at the University of British Columbia, Lucija Tomljenovic, and neuroscientist Christopher Shaw, who have closely looked into Gardasil, have argued that the risks from the vaccine seem to significantly outweigh the as-yet-unproven long-term benefits.

    In a 2012 comment published in the American Journal of Public Health, they took issue with “incomplete and inaccurate” data and poorly designed trials.

    Vaccination is unjustified if the vaccine carries any substantial risk, as healthy teenagers face little to no risk of dying from cervical cancer.

    Risk-benefit analyses must be conducted to ascertain the overall balance of benefits and harms on both individual and societal levels.

    Reprinted with permission from The Epoch Times. Dr. Yuhong Dong, a medical doctor who also holds a doctorate in infectious diseases in China, is the chief scientific officer and co-founder of a Swiss biotech company and former senior medical scientific expert for antiviral drug development at Novartis Pharma in Switzerland.

    If you or your child suffered harm after receiving the Gardasil HPV vaccine, you may have a legal claim. Please visit Wisner Baum for a free case evaluation. Click here to watch a Gardasil litigation update interview with Wisner Baum Senior Partner Bijan Esfandiari.

    The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of Children's Health Defense.

    https://childrenshealthdefense.org/defender/truth-hpv-vaccine-part-2-et/

    https://donshafi911.blogspot.com/2024/01/the-truth-about-hpv-vaccination-part-2.html
    The Truth About HPV Vaccination, Part 2: Studies Link the Vaccines to Neurological, Autoimmune Disorders Researchers who looked closely into the Gardasil HPV vaccine concluded the risks from the vaccine seem to significantly outweigh the as-yet-unproven long-term benefits. The Epoch Times Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free. By Dr. Yuhong Dong Editor’s Note: This second installment in a multi-part series about the human papillomavirus, or HPV, vaccine examines studies that link the vaccines to increased risk of serious neurological and autoimmune disorders. Read Part 1 here. Summary of key facts A Danish review of 79,102 female and 16,568 male subjects, found human papillomavirus (HPV) vaccines had significantly increased rates of serious nervous system disorders. Postural orthostatic tachycardia syndrome (POTS) and complex regional pain syndrome were judged “definitely associated” with the HPV vaccine. A large Danish and Swedish study including nearly 300,000 girls found a significant association between the HPV vaccine and increased rates of Bechet’s syndrome (rate ratio 3.37), Raynaud’s disease (1.67) and type 1 diabetes (1.29). A large study including 3 million Danish and Swedish women aged 18 to 44, identified seven adverse events with statistically significant increased risks following HPV vaccination: Hashimoto’s thyroiditis, celiac disease, lupus erythematosus, pemphigus vulgaris, Addison’s disease, Raynaud’s disease and encephalitis, myelitis, or encephalomyelitis. A 2017 French study of over 2.2 million young girls found evidence of a 3.78-fold increased risk of Guillain-Barré syndrome (GBS). A 2011 U.S. study found nearly a two-and-a-half to 10 times greater risk of acquiring GBS within six weeks post-Gardasil vaccination. While the underlying mechanisms causing these autoimmune reactions are not yet fully understood, some researchers speculate that the sizable overlap in protein sequences between the HPV and the human genome may cause the immune system to attack itself. Others are concerned that the adjuvants (such as aluminum) used to attract the attention of the immune system may be causing harm. Neurological and autoimmune disorders Danish review found increased nervous system disorder In 2020, a group of Danish scientists conducted a systematic review of the overall benefits and harms of HPV vaccines. Twenty-four eligible randomized controlled clinical studies were obtained, with a total of 95,670 participants, mostly women, and 49 months mean weighted follow-up. Almost all controls were given an active comparator vaccine (typically a hepatitis vaccine with a comparable aluminum-based adjuvant). Given that the adjuvant is highly immunogenic by design (it is meant to grab the attention of the immune system), this trial design makes it difficult to detect an excess risk with the HPV vaccines. Without true controls (such as a saline placebo), the real risks of HPV vaccination cannot be accurately assessed. In the vaccine group, 367 cancers were detected, compared to 490 in the comparator group. Younger participants (15 to 29) seemed to benefit more from the vaccine concerning preventing moderate HPV-related intraepithelial neoplasia compared to older participants (ages 21 to 72). Younger participants also had fewer fatal harms. Even though the studies were flawed in their design, at four years post-vaccination, those who had received the HPV vaccines had significantly increased rates of serious nervous system disorders: 49%, as well as general harms totaling 7%. The serious harms that were judged “definitely associated” with HPV vaccines were postural orthostatic tachycardia syndrome and complex regional pain syndrome. POTS had a nearly twofold increase in the vaccinated group. By July 2017, only two-thirds of the results from HPV vaccine trials had been published, and only about half the results had been posted, due to manuscript length limitations, reporting bias and confounding journal articles offering a limited view of trial outcomes. This Danish systematic review compiled data from all the HPV trials to offer a summary of the evidence thus far. Nevertheless, the investigators acknowledged that despite three years of work, the limitations of their analysis remained. These included reporting bias, incomplete reporting, data fragmentation and limited trial follow-up. These investigators similarly note that the trials were powered to assess the benefits of HPV vaccination, not rare harms. The degree to which benefits outweigh risks is therefore unknown. They concluded that future research should carefully evaluate the harms following Gardasil 9 compared to Gardasil because the former contains more than double the virus proteins and aluminum-containing adjuvant than the same dose of Gardasil. RFK Jr. and Brian Hooker Vax-Unvax RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax” Order Now Large studies reveal autoimmune events In 2009, the HPV4 vaccine was integrated into the Danish childhood vaccination program. Since then, two large cohort studies on the HPV4 vaccine adverse events have been carried out using the hospital-based healthcare registries of Denmark and Sweden. The first study in Denmark and Sweden included 296,826 girls aged 10 to 17 who received a total of 696,420 HPV4 vaccine doses. The scientists evaluated rate ratios for autoimmune events and found no significant association for 20 out of 23 events. They found a significant association between the HPV4 vaccine and Bechet’s syndrome (rate ratio 3.37), Raynaud’s disease (1.67) and type 1 diabetes (1.29). But after further review, they concluded that there was insufficient evidence for a causal association, because of the weakness of the signal and the lack of an underlying mechanism to explain biological plausibility. In a second large cohort study, the same team expanded their research to more than 3 million Danish and Swedish adult women aged 18 to 44. The authors identified seven adverse events with statistically significant increased risks following HPV4 vaccination: Hashimoto’s thyroiditis, celiac disease, lupus erythematosus, pemphigus vulgaris, Addison’s disease, Raynaud’s disease and encephalitis, myelitis or encephalomyelitis. After sensitivity analyses, the association between HPV4 vaccination and celiac disease was the most robust finding. Celiac disease is a condition where a person’s immune system attacks the body’s own gut after eating gluten. As the graph below shows, the scientists used two risk periods after HPV4 vaccination: the first 180 days and after. 1 time since first dose HPV4 vaccine coeliac cases Time since the first dose of the HPV4 vaccine for vaccinated coeliac cases in a cohort of Danish and Swedish women. Credit: Journal of Internal Medicine The authors noted that the observed 56% increased risk of celiac disease “was strong, and the increase was strikingly similar in both risk periods after vaccination.” Celiac disease is underdiagnosed in Denmark. So one possible explanation is that vaccination visits allow a chance for this and other conditions to be diagnosed and explored. This explanation suggests that the association between the HPV vaccine and autoimmune disorders may be coincidental. However, given the lack of any real control groups in these studies, as well as the growing body of scientific literature from countries around the world showing problems with the HPV vaccine, dismissing these safety signals as coincidence seems short-sighted. Large French study and U.S. VAERS study identify risks of Guillain-Barré Syndrome The concern about autoimmune disease adverse events has contributed to low HPV vaccination uptake in France. A 2017 study of over 2.2 million young girls in France found troubling evidence of a link with Guillain-Barré syndrome. GBS is a condition that arises when our own antibodies attack the nerves. The incidence of GBS was found to be 1.4 per 100,000 person-years among the vaccinated girls compared to 0.4 per 100,000 among the unvaccinated, resulting in an increased risk of GBS of more than 200%. The association appeared to be “particularly marked in the first months following vaccination.” This finding is corroborated by the pattern of adverse reactions reported worldwide. Data from a large number of case reports document similar serious adverse events associated with Gardasil administration, with nervous system disorders of autoimmune origin being the most frequently reported. A 2011 U.S. study found that the estimated weekly reporting rate of post-Gardasil GBS within the first six weeks (6.6 per 10,000,000) was higher than in the general population, and higher than post-Menactra and post-influenza vaccinations. In particular, there was nearly a two-and-a-half to 10 times greater risk of acquiring GBS within six weeks after vaccination, compared to the general population. Additionally, the study found Gardasil vaccination was associated with approximately eight-and-a-half times more emergency department visits, 12.5 times more hospitalizations, 10 times more life-threatening events and 26.5 times more disability than the Menactra vaccination. Plausible mechanisms of harm Despite the conflicting data in the scientific literature to date, it is clear that the HPV vaccines can cause autoimmune disorders in susceptible people. But how? Autoimmunity has been reported as a complication of natural infection as well as virus vaccination. This phenomenon has been observed with many viruses, including the Epstein-Barr virus, COVID-19 and HPV. According to a 2019 study, the HPV vaccine contains epitopes — portions of the virus proteins — that overlap with the human proteins. This means that if we develop antibodies to those viruses, we may also generate autoantibodies to our own cells, which is the root cause of autoimmune dysfunction. The study showed that most of the immunoreactive HPV L1 epi­topes are overlapping peptides present in human proteins. The authors explained that this “unexpected enormous size of the peptide overlap between the HPV epitopes and human proteins” is relevant, and may be why a wide variety of autoimmune diseases have been reported post-HPV vaccination, including ovarian failure, systemic lupus erythematosus, breast cancer and sudden death, among others. Why some people develop these conditions and others do not is unclear. The authors suggest that vaccines should target the few peptides that do not overlap with human proteins, but which do overlap with the other HPVs. Despite this overlap and the potential for causing autoimmune disease, medical doctors usually ignore or dismiss the connection. We are told that these diseases are rare. The human body has something called immune tolerance. This protects a person’s immune system against attacking itself. Therefore, HPV infection is also “immune tolerated,” which means it lays dormant for some time until it becomes cancerous. HPV vaccination was actually designed with this immune tolerance in mind. Given the human body’s built-in defenses against autoimmune conditions, vaccinology requires an immunogenic catalyst to get the body’s attention. This is the job of an adjuvant. An adjuvant is an ingredient used in a vaccine that the body recognizes as foreign. It is added to vaccines so that the body will mount a stronger immune response. The idea is that in attacking the adjuvant, the body will also recognize other vaccine ingredients (in this case, purified HPV proteins). In addition, the antigen dose is much higher than in natural infections and the capsids in the vaccine are directly exposed to systemic immune responses as opposed to the virus staying relatively hidden within the natural barrier of the skin following infection. The vaccine was well-designed to trigger an immune response, but this advantage may come at a cost: Generating antibodies to HPV proteins through vaccination could, theoretically, set the stage for an autoimmune attack. Link between HPV-vaccine-associated nervous system dysfunction and autoimmunity A December 2022 Danish and German study was designed to elucidate a possible mechanism of harm. The lead author, Dr. Jesper Mehlsen, a specialist in treating autoimmune conditions, noted that the HPV major capsid L1s antigen resembles human autonomic nerve receptors, including G-protein coupled receptors (GPCR). According to the researchers, in the past several years, case series of suspected vaccination side effects have pointed to three disease entities: POTS, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and complex regional pain syndrome. These syndromes may be associated with neuroendocrine GPCR antibodies. From 2011 to 2018, researchers saw 845 patients (839 females, six males) with suspected side effects following the HPV4 vaccine. The control group included vaccinated people without side effects. Moderate to severe fatigue was recorded in 83.3% of the patients but in none of the controls. A high prevalence of symptoms, such as dizziness (91%), heart palpitations (71%), nausea (80%) and hyperactive bladder suggested that the patients were experiencing some kind of autonomic dysfunction. Autonomic dysfunction occurs when the part of the nervous system that controls well-being and balance does not function properly. 2 most frequent symptoms hpv vaccine Most frequent symptoms reported by 612 patients in Denmark. Credit: Journal of Autoimmunity Twenty-four percent higher antinuclear antibodies (ANA, a common type of autoantibodies) were found in patients, suggesting possible autoimmunity. 3 antinuclear antibodies HPV vaccines A larger proportion of the symptomatic patients were found with a common type of autoantibodies compared to healthy controls. Credit: Journal of Autoimmunity Antibodies against the adrenergic ß-2-receptor and muscarinic M-2 receptors were also found significantly higher in patients. Many of the symptoms, including immune activation and autonomic dysregulation, could be mediated or aggravated by dysregulated autoantibodies against adrenergic receptors and impaired peripheral adrenergic function. The authors suggested that girls and women with probable side effects of HPV vaccination have symptoms and biological markers compatible with an autoimmune disease closely resembling that seen in ME/CFS. Interestingly, people who already had HPV infections at some point appeared to be at greater risk for adverse events following vaccination. The authors noted that “prior disease may precondition some individuals for vaccine-related adverse events.” They also noted that some of the adverse events resembled long-COVID symptoms. Universal HPV vaccination called into question Academic researcher at the University of British Columbia, Lucija Tomljenovic, and neuroscientist Christopher Shaw, who have closely looked into Gardasil, have argued that the risks from the vaccine seem to significantly outweigh the as-yet-unproven long-term benefits. In a 2012 comment published in the American Journal of Public Health, they took issue with “incomplete and inaccurate” data and poorly designed trials. Vaccination is unjustified if the vaccine carries any substantial risk, as healthy teenagers face little to no risk of dying from cervical cancer. Risk-benefit analyses must be conducted to ascertain the overall balance of benefits and harms on both individual and societal levels. Reprinted with permission from The Epoch Times. Dr. Yuhong Dong, a medical doctor who also holds a doctorate in infectious diseases in China, is the chief scientific officer and co-founder of a Swiss biotech company and former senior medical scientific expert for antiviral drug development at Novartis Pharma in Switzerland. If you or your child suffered harm after receiving the Gardasil HPV vaccine, you may have a legal claim. Please visit Wisner Baum for a free case evaluation. Click here to watch a Gardasil litigation update interview with Wisner Baum Senior Partner Bijan Esfandiari. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of Children's Health Defense. https://childrenshealthdefense.org/defender/truth-hpv-vaccine-part-2-et/ https://donshafi911.blogspot.com/2024/01/the-truth-about-hpv-vaccination-part-2.html
    CHILDRENSHEALTHDEFENSE.ORG
    The Truth About HPV Vaccination, Part 2: Studies Link the Vaccines to Neurological, Autoimmune Disorders
    Researchers who looked closely into the Gardasil HPV vaccine concluded the risks from the vaccine seem to significantly outweigh the as-yet-unproven long-term benefits.
    Like
    1
    0 Comentários 0 Compartilhamentos 12528 Visualizações
  • The Truth About HPV Vaccination, Part 1: How Safe Is It, Really?
    This first installment in a multi-part series about the human papillomavirus, or HPV, vaccine explores peer-reviewed scientific literature that reveals serious safety concerns about a vaccine widely regarded as safe.

    The Epoch Times

    Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.

    By Yuhong Dong

    The decline of public trust in COVID-19 vaccines significantly impacts vaccination rates against routine childhood diseases. This multiple-part series explores the international research done over the past two decades on the human papillomavirus (HPV) vaccine — believed to be one of the most effective vaccines developed to date.

    Summary of Key Facts

    This multiple-part series offers a thorough analysis of concerns raised about HPV vaccination following the global HPV campaign, which commenced in 2006.
    In the U.S., the HPV vaccine was reported to have a disproportionately higher percentage of adverse events of fainting and blood clots in the veins. The U.S. Food and Drug Administration (FDA) acknowledges that fainting can happen following the HPV vaccine, and recommends sitting or lying down to get the shot, then waiting for 15 minutes afterward.
    International scientists found that the Centers for Disease Control and Prevention’s (CDC) Vaccine Adverse Event Reporting System (VAERS) logged a substantial increase in reports of premature ovarian failure from 1.4 per year before 2006 to 22.2 per year after the HPV vaccine approval, yielding a Proportional Reporting Ratio of 46.1.
    The HPV vaccine is widely regarded as one of the most effective vaccines developed to date. Nevertheless, safety issues have been raised following its approval, and in response, additional research has been published and litigation has been brought on behalf of those with a vaccine injury.

    In this HPV vaccine series, Parts I and II explain how the vaccine works and the evidence suggesting there may be legitimate safety concerns. The remaining parts present questions about real-world vaccine effectiveness and identify specific ingredients which may pose harm.

    The information presented here is drawn from peer-reviewed scientific literature from the U.S., Australia, Denmark, Sweden, France and Japan, as well as statistics published by public health agencies in each of these countries.

    More than 100 hours of research and internal peer review among scientists with experience in infectious diseases, virology, clinical trials and vaccine epidemiology have been invested in presenting this summary of the evidence.

    Large registry-based studies have identified plausible associations between HPV vaccination and autoimmune conditions, including premature ovarian insufficiency or premature ovarian failure, Guillain-Barré syndrome (GBS), postural orthostatic tachycardia syndrome and chronic regional pain syndrome.

    While it is easy to be enthusiastic about recent advances in human vaccine technology, we should keep in mind that achieving real and lasting good health is much more than just the absence of a certain virus.

    RFK Jr. and Brian Hooker Vax-Unvax
    RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax”

    Order Now

    What is HPV?

    According to the CDC, HPV is the most common sexually transmitted infection in the U.S.

    HPV is a small DNA virus infecting human cutaneous epithelial cells in the mucosa and skin. More than 150 strains of the HPV virus have been identified.

    HPV infection is so common that the majority of sexually active people will get it at some point in their lives, even if they have only one or very few sexual partners. It can spread through sexual intercourse and oral sex. It can also pass between people through skin-to-skin contact, even by people who have no symptoms.

    HPV infection causes genital warts, some of which can turn into cancer. For the most part, however, HPV infection is benign. More than 90% of HPV infections cause no clinical symptoms and are self-limited, meaning the virus is cleared by the body via natural immunological defenses.

    HPV-associated cancers

    High-risk HPV types (types 16, 18 and others) can cause cervical cell abnormalities that are precursors to cancers.

    Type 16 is associated with approximately 50% of cervical cancers worldwide, and types 16 and 18 together are linked to 66% of cervical cancers.

    An additional five high-risk types, 31, 33, 45, 52 and 58, are linked with another 15% of cervical cancers and 11% of all HPV-associated cancers.

    Infection with a high-risk HPV type is associated with a higher chance of the development of cervical cancer but, by itself, HPV infection is not the sole risk factor to cause cancer. There are many other reasons, as discussed in this paper.

    Given the prevalence of infection, it is unsurprising that globally, cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570,000 women were diagnosed with cervical cancer worldwide and more than 300,000 died of the disease.

    In the U.S., nearly 50,000 new HPV-associated cancers occur annually, with women infected at a slightly higher rate than men.

    But in 9 out of 10 cases, HPV goes away within two years without causing health problems.

    Only persistent HPV infections may lead to cancer. These infections evade the immune system’s innate cell-mediated defenses.

    The incidence of cervical cancer can be controlled as a result of the implementation of routine testing and screening, including Pap and DNA tests.

    HPV vaccines

    Three HPV vaccines — bivalent HPV vaccine (Cervarix, 2vHPV), quadrivalent HPV vaccine (Gardasil, 4vHPV or HPV4) and 9-valent HPV vaccine (Gardasil 9, 9vHPV) — have been licensed by the FDA.

    The HPV vaccine uses recombinant technology to assemble the shell of the virus — L1 capsid protein. These viral-like particles do not contain the virus genome and are not infectious.

    Cervarix, developed by GlaxoSmithKline, is a bivalent vaccine against HPV types 16 and 18, that was pulled from the U.S. market in 2016 due to “very low market demand.”

    Merck’s original Gardasil vaccine was designed to prevent infections from four strains (types 6, 11, 16 and 18).

    On June 8, 2006, after the FDA’s fast-tracked review, Gardasil was approved for use in females ages 9 to 26 for the prevention of cervical, vulvar and vaginal cancers.

    According to the label accompanying the vaccine, the ingredients in Merck’s first Gardasil vaccine were proteins of HPV, amorphous aluminum hydroxyphosphate sulfate, yeast protein, sodium chloride, L-histidine, polysorbate 80, sodium borate and water for injection.

    On Oct. 16, 2009, the FDA approved Gardasil (HPV4) for use in boys ages 9 through 26 for the prevention of genital warts caused by HPV types 6 and 11, but not for cancer.

    In 2010, it approved Gardasil for the prevention of anal cancer in males and females ages 9 to 26.

    Four years later, the FDA approved an updated vaccine, Merck’s Gardasil 9, for use in girls ages 9 to 26 and boys ages 9 to 15 for the prevention of cervical, vaginal and anal cancers.

    Gardasil 9 contains the same ingredients as Gardasil, but offers protection against nine HPV strains, adding five additional types (HPV types 31, 33, 45, 52 and 58).

    The current HPV vaccination schedule recommended by the CDC is two doses for both boys and girls aged 11 or 12. However, it is approved for children as young as 9. The second dose is given 6 to 12 months after the first.

    For those aged 15 and above, a three-dose schedule is implemented at one- to two-month and six-month intervals, although antibody-level studies suggest that two doses are sufficient.

    The vaccine prompts the body to produce neutralizing antibodies against HPV. Antibody responses appear to peak seven months after the first dose (or one month after the third dose). The vaccine-induced antibody levels appear to be 10 to 100 times higher than those after natural infection.

    The high vaccine effectiveness (90 to 98%) against the fast-growing, abnormal cells which may cause precancerous lesions in people ages 16 to 26 suggested that the best timing for vaccination was to give it to patients before they became sexually active.

    HPV VAERS reports from 2 large countries

    U.S. HPV vaccine adverse events

    On Aug. 19, 2009, the Journal of the American Medical Association published an article authored by scientists from the FDA and CDC that reviewed the safety data for Gardasil for adverse events reported to VAERS between June 2006 through December 2008.

    During that time, there were 12,424 reports of adverse events. Of these, 772 (6.2%) were serious.

    VAERS is a passive surveillance system, which is subject to multiple limitations, including underreporting, unconfirmed diagnosis, lack of denominator data and no unbiased comparison groups.

    Nevertheless, it is a useful and important tool for detecting postmarket safety issues with vaccines.

    A disproportionately high percentage of Gardasil VAERS reports were of syncope (fainting) and venous thromboembolic events (blood clots in the veins) compared with other vaccines. There were 8.2 syncope events per 100,000 HPV doses and 0.2 venous thromboembolic events per 100,000 HPV doses reported, respectively.

    The Gardasil package insert includes a warning about fainting, fever, dizziness, nausea and headaches (page 1) and notes at least the following adverse reactions reported during postmarketing surveillance (section 6.2): Guillain-Barré syndrome, transverse myelitis, motor neuron disease, venous thromboembolic events, pancreatitis and autoimmune disorders.

    Australia HPV vaccines adverse events

    In 2007, Australia reported an annual adverse drug reaction rate of 7.3/100,000, the highest since 2003, representing an 85% increase from 2006.

    Per the analysis of the Adverse Drug Reactions System database by the Australian Department of Health and Aging, this increase was “almost entirely due to” reports following the national rollout of the three-dose HPV vaccination program for young females in April 2007; 705 of the 1,538 adverse drug reactions reported that year were from the Gardasil vaccine.

    1 vaccine adverse events australia chart
    In Australia, the ADR increase in 2007 was almost entirely due to the three-dose HPV vaccination program for females aged 12 to 26 years in April 2007. Credit: Australian Government Department of Health and Aged Care.
    Moreover, though people may take different vaccines other than HPV, the HPV vaccine was the only suspected vaccine to cause adverse reactions in 96% of records. Twenty-nine percent had causality ratings of “certain” or “probable” and 6% were defined as “serious.”

    2 vaccine types vaccine suspected chart
    In these HPV-induced ADRs, 674 were suspected to be related to HPV vaccines, 203 had causality ratings of “certain” or “probable,” and 43 were defined as “serious.” Credit: Australian Government Department of Health and Aged Care.
    Japan withdraws recommendation, vaccine acceptance plunged

    In 2013, the Japanese raised concerns about a variety of widely reported post-vaccination serious adverse events. This led the government to suspend recommending the HPV vaccine for six years. Vaccine acceptance of HPV in Japan plunged significantly after 2013, from 42.9% to 14.3%, or from 65.4% to 3.9%.

    Researchers around the world also started to investigate HPV safety. A World Health Organization (WHO) position paper released on July 14, 2017, concluded that the HPV vaccines were “extremely safe.”

    The same report estimated approximately 1.7 cases of anaphylaxis per million HPV doses, that no association with GBS was found, and that syncope (fainting) was “established as a common anxiety or stress-related reaction to the injection.”

    In the spring of 2022, Japan announced it was relaunching its HPV vaccination drive. Mainstream news outlets reported that for thousands of women, the cost of caution may have led to preventable HPV-induced cancers and an estimated 5,000 to 5,700 deaths.

    However, a true risk-benefit analysis would also consider the number of serious adverse events prevented by putting the program on hold. The question remains: Was Japan’s caution warranted, or should their national vaccination program have continued?

    Ovarian insufficiency

    Concerns that the vaccine may be negatively affecting fertility have been detailed in the scientific literature.

    In 2014, a peer-reviewed case series describing premature ovarian failure among Australian women following HPV vaccination was published in the Journal of Investigative Medicine.

    This prompted other researchers to systematically examine the VAERS data to see if there was a connection between premature ovarian failure and Gardasil. Their study found a “potential safety signal” and concluded that “further investigations are warranted.”

    VAERS analysis on ovarian failure

    Two recent publications based on VAERS reports (first study, second study) found that events with a probable autoimmune background were significantly more frequent after HPV vaccination compared to other vaccinations.

    The team of international scientists that did the second study evaluated reports between 1990 and 2018. They found that among the 228,341 premature ovarian failure reports, 0.1% was considered to be associated with HPV vaccination with a median age of 15 years and the time to onset was 20.5 days following vaccination.

    The primary symptoms were amenorrhea (80.4%) and premature menopause (15.3%).

    Most strikingly, the mean number of premature ovarian failure cases increased significantly from 1.4 per year prior to 2006 to 22.2 per year after the HPV vaccine was approved, with a proportional reporting ratio of 46.

    The investigators noted that the WHO and CDC declared the HPV vaccine safe regardless of lacking adequate research into safety concerns.

    For example, the authors note that in a CDC-sponsored VAERS study, 17 cases of premature ovarian failure were identified but 15 were excluded due to insufficient information to confirm the diagnosis. A separate observational study using the Vaccine Safety Datalink found no increased risk.

    But this study was too underpowered to detect a signal. In addition, a cross-sectional survey study using National Health and Nutrition Examination Survey data relied on an inaccurate measurement of premature ovarian failure and self-reported HPV vaccination.

    In summary, the researchers detected a strong safety signal even after accounting for a potential upswing in reports due to media coverage after the product launch (they refer to this as “notoriety bias”).

    Because VAERS is a passive reporting system, the data may be incomplete and are often unconfirmed by physicians. Therefore, this study cannot provide a definitive link between HPV vaccination and premature ovarian insufficiency or premature ovarian failure but does generate a hypothetical link.

    The authors of the second study conclude by insisting that “this signal warrants well-designed and appropriate epidemiological research.” They note that “if the signal is confirmed, the risk is small compared to the lifetime risk of cervical cancer.”

    However, the benefit-risk profile on an individual level is not uniform.

    Given the health impacts of premature ovarian insufficiency and premature ovarian failure — some of which may be irreversible — and the declining mortality rate for cervical cancer even in the prevaccine era, the risk-benefit profile for HPV vaccination remains unclear.

    3 case reports on ovarian insufficiency

    In the 2014 investigation mentioned above, a general practitioner in Australia noticed that three girls developed premature ovarian insufficiency following HPV4 vaccination.

    As a result of vaccination, each of the girls (ages 16, 16 and 18) had been prescribed oral contraception to treat menstrual cycle irregularities. Typically, women present with amenorrhea (no periods) or oligomenorrhea (infrequent periods) as the initial symptom of premature ovarian insufficiency.

    One girl had irregular periods following three doses of HPV vaccination. She then became amenorrheic and was diagnosed with premature ovarian insufficiency.

    Another girl’s periods were “like clockwork” until after the third HPV dose, which she received at age 15. Her first cycle after being vaccinated for the third time started two weeks late, and her next cycle was two months late. The final cycle began nine months later. The patient had no family history of early menopause.

    She was diagnosed with premature ovarian failure at 16. Lab work found hormone levels consistent with those of postmenopausal women, but her bone mineral density was normal.

    The authors of this case series noted that in preclinical studies of HPV4, the five-week-old rats only conceived one litter and the only available toxicology studies appear to be on the male rodent reproductive system.

    However, only two of three doses were administered prior to mating, and the overall fecundity was 95%, slightly lower than the control rats (98%) that received no vaccination prior to mating.

    The dose tolerance recommendations were based on an average weight of 50 kilograms for an adolescent girl but failed to take into account that HPV4 is administered to girls ages 9 to 13 years, who range in weight from 28 to 46 kilograms.

    Danish retrospective cohort study finds no link

    A 2021 study also evaluated premature ovarian insufficiency in a nationwide cohort of nearly 1 million Danish females ages 11 to 34 years.

    The researchers used Cox proportional hazard regression to detect an increased risk of premature ovarian insufficiency diagnosis by HPV4 vaccination status during the years 2007-2016. The hazard ratio for premature ovarian insufficiency (vaccinated versus unvaccinated) was 0.96.

    One limitation was that data on age at menarche (first menstruation) and oral contraceptive use were not available. Girls who had not yet reached menarche would not be at risk for premature ovarian insufficiency, of course.

    The authors excluded girls under age 15 in a sensitivity analysis and still found no signal, concluding that no association was found between HPV4 vaccination and premature ovarian insufficiency.

    Reprinted with permission from The Epoch Times. Dr. Yuhong Dong, a medical doctor who also holds a doctorate in infectious diseases from China, is the chief scientific officer and co-founder of a Swiss biotech company and a former senior medical scientific expert for antiviral drug development at Novartis Pharma in Switzerland.

    If you or your child suffered harm after receiving the Gardasil HPV vaccine, you may have a legal claim. Please visit Wisner Baum for a free case evaluation. Click here to watch a Gardasil litigation update interview with Wisner Baum Senior Partner Bijan Esfandiari.

    The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of Children's Health Defense.

    https://childrenshealthdefense.org/defender/hpv-vaccine-safety-concerns-part-1-et/


    https://donshafi911.blogspot.com/2024/01/the-truth-about-hpv-vaccination-part-1.html
    The Truth About HPV Vaccination, Part 1: How Safe Is It, Really? This first installment in a multi-part series about the human papillomavirus, or HPV, vaccine explores peer-reviewed scientific literature that reveals serious safety concerns about a vaccine widely regarded as safe. The Epoch Times Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free. By Yuhong Dong The decline of public trust in COVID-19 vaccines significantly impacts vaccination rates against routine childhood diseases. This multiple-part series explores the international research done over the past two decades on the human papillomavirus (HPV) vaccine — believed to be one of the most effective vaccines developed to date. Summary of Key Facts This multiple-part series offers a thorough analysis of concerns raised about HPV vaccination following the global HPV campaign, which commenced in 2006. In the U.S., the HPV vaccine was reported to have a disproportionately higher percentage of adverse events of fainting and blood clots in the veins. The U.S. Food and Drug Administration (FDA) acknowledges that fainting can happen following the HPV vaccine, and recommends sitting or lying down to get the shot, then waiting for 15 minutes afterward. International scientists found that the Centers for Disease Control and Prevention’s (CDC) Vaccine Adverse Event Reporting System (VAERS) logged a substantial increase in reports of premature ovarian failure from 1.4 per year before 2006 to 22.2 per year after the HPV vaccine approval, yielding a Proportional Reporting Ratio of 46.1. The HPV vaccine is widely regarded as one of the most effective vaccines developed to date. Nevertheless, safety issues have been raised following its approval, and in response, additional research has been published and litigation has been brought on behalf of those with a vaccine injury. In this HPV vaccine series, Parts I and II explain how the vaccine works and the evidence suggesting there may be legitimate safety concerns. The remaining parts present questions about real-world vaccine effectiveness and identify specific ingredients which may pose harm. The information presented here is drawn from peer-reviewed scientific literature from the U.S., Australia, Denmark, Sweden, France and Japan, as well as statistics published by public health agencies in each of these countries. More than 100 hours of research and internal peer review among scientists with experience in infectious diseases, virology, clinical trials and vaccine epidemiology have been invested in presenting this summary of the evidence. Large registry-based studies have identified plausible associations between HPV vaccination and autoimmune conditions, including premature ovarian insufficiency or premature ovarian failure, Guillain-Barré syndrome (GBS), postural orthostatic tachycardia syndrome and chronic regional pain syndrome. While it is easy to be enthusiastic about recent advances in human vaccine technology, we should keep in mind that achieving real and lasting good health is much more than just the absence of a certain virus. RFK Jr. and Brian Hooker Vax-Unvax RFK Jr. and Brian Hooker’s New Book: “Vax-Unvax” Order Now What is HPV? According to the CDC, HPV is the most common sexually transmitted infection in the U.S. HPV is a small DNA virus infecting human cutaneous epithelial cells in the mucosa and skin. More than 150 strains of the HPV virus have been identified. HPV infection is so common that the majority of sexually active people will get it at some point in their lives, even if they have only one or very few sexual partners. It can spread through sexual intercourse and oral sex. It can also pass between people through skin-to-skin contact, even by people who have no symptoms. HPV infection causes genital warts, some of which can turn into cancer. For the most part, however, HPV infection is benign. More than 90% of HPV infections cause no clinical symptoms and are self-limited, meaning the virus is cleared by the body via natural immunological defenses. HPV-associated cancers High-risk HPV types (types 16, 18 and others) can cause cervical cell abnormalities that are precursors to cancers. Type 16 is associated with approximately 50% of cervical cancers worldwide, and types 16 and 18 together are linked to 66% of cervical cancers. An additional five high-risk types, 31, 33, 45, 52 and 58, are linked with another 15% of cervical cancers and 11% of all HPV-associated cancers. Infection with a high-risk HPV type is associated with a higher chance of the development of cervical cancer but, by itself, HPV infection is not the sole risk factor to cause cancer. There are many other reasons, as discussed in this paper. Given the prevalence of infection, it is unsurprising that globally, cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570,000 women were diagnosed with cervical cancer worldwide and more than 300,000 died of the disease. In the U.S., nearly 50,000 new HPV-associated cancers occur annually, with women infected at a slightly higher rate than men. But in 9 out of 10 cases, HPV goes away within two years without causing health problems. Only persistent HPV infections may lead to cancer. These infections evade the immune system’s innate cell-mediated defenses. The incidence of cervical cancer can be controlled as a result of the implementation of routine testing and screening, including Pap and DNA tests. HPV vaccines Three HPV vaccines — bivalent HPV vaccine (Cervarix, 2vHPV), quadrivalent HPV vaccine (Gardasil, 4vHPV or HPV4) and 9-valent HPV vaccine (Gardasil 9, 9vHPV) — have been licensed by the FDA. The HPV vaccine uses recombinant technology to assemble the shell of the virus — L1 capsid protein. These viral-like particles do not contain the virus genome and are not infectious. Cervarix, developed by GlaxoSmithKline, is a bivalent vaccine against HPV types 16 and 18, that was pulled from the U.S. market in 2016 due to “very low market demand.” Merck’s original Gardasil vaccine was designed to prevent infections from four strains (types 6, 11, 16 and 18). On June 8, 2006, after the FDA’s fast-tracked review, Gardasil was approved for use in females ages 9 to 26 for the prevention of cervical, vulvar and vaginal cancers. According to the label accompanying the vaccine, the ingredients in Merck’s first Gardasil vaccine were proteins of HPV, amorphous aluminum hydroxyphosphate sulfate, yeast protein, sodium chloride, L-histidine, polysorbate 80, sodium borate and water for injection. On Oct. 16, 2009, the FDA approved Gardasil (HPV4) for use in boys ages 9 through 26 for the prevention of genital warts caused by HPV types 6 and 11, but not for cancer. In 2010, it approved Gardasil for the prevention of anal cancer in males and females ages 9 to 26. Four years later, the FDA approved an updated vaccine, Merck’s Gardasil 9, for use in girls ages 9 to 26 and boys ages 9 to 15 for the prevention of cervical, vaginal and anal cancers. Gardasil 9 contains the same ingredients as Gardasil, but offers protection against nine HPV strains, adding five additional types (HPV types 31, 33, 45, 52 and 58). The current HPV vaccination schedule recommended by the CDC is two doses for both boys and girls aged 11 or 12. However, it is approved for children as young as 9. The second dose is given 6 to 12 months after the first. For those aged 15 and above, a three-dose schedule is implemented at one- to two-month and six-month intervals, although antibody-level studies suggest that two doses are sufficient. The vaccine prompts the body to produce neutralizing antibodies against HPV. Antibody responses appear to peak seven months after the first dose (or one month after the third dose). The vaccine-induced antibody levels appear to be 10 to 100 times higher than those after natural infection. The high vaccine effectiveness (90 to 98%) against the fast-growing, abnormal cells which may cause precancerous lesions in people ages 16 to 26 suggested that the best timing for vaccination was to give it to patients before they became sexually active. HPV VAERS reports from 2 large countries U.S. HPV vaccine adverse events On Aug. 19, 2009, the Journal of the American Medical Association published an article authored by scientists from the FDA and CDC that reviewed the safety data for Gardasil for adverse events reported to VAERS between June 2006 through December 2008. During that time, there were 12,424 reports of adverse events. Of these, 772 (6.2%) were serious. VAERS is a passive surveillance system, which is subject to multiple limitations, including underreporting, unconfirmed diagnosis, lack of denominator data and no unbiased comparison groups. Nevertheless, it is a useful and important tool for detecting postmarket safety issues with vaccines. A disproportionately high percentage of Gardasil VAERS reports were of syncope (fainting) and venous thromboembolic events (blood clots in the veins) compared with other vaccines. There were 8.2 syncope events per 100,000 HPV doses and 0.2 venous thromboembolic events per 100,000 HPV doses reported, respectively. The Gardasil package insert includes a warning about fainting, fever, dizziness, nausea and headaches (page 1) and notes at least the following adverse reactions reported during postmarketing surveillance (section 6.2): Guillain-Barré syndrome, transverse myelitis, motor neuron disease, venous thromboembolic events, pancreatitis and autoimmune disorders. Australia HPV vaccines adverse events In 2007, Australia reported an annual adverse drug reaction rate of 7.3/100,000, the highest since 2003, representing an 85% increase from 2006. Per the analysis of the Adverse Drug Reactions System database by the Australian Department of Health and Aging, this increase was “almost entirely due to” reports following the national rollout of the three-dose HPV vaccination program for young females in April 2007; 705 of the 1,538 adverse drug reactions reported that year were from the Gardasil vaccine. 1 vaccine adverse events australia chart In Australia, the ADR increase in 2007 was almost entirely due to the three-dose HPV vaccination program for females aged 12 to 26 years in April 2007. Credit: Australian Government Department of Health and Aged Care. Moreover, though people may take different vaccines other than HPV, the HPV vaccine was the only suspected vaccine to cause adverse reactions in 96% of records. Twenty-nine percent had causality ratings of “certain” or “probable” and 6% were defined as “serious.” 2 vaccine types vaccine suspected chart In these HPV-induced ADRs, 674 were suspected to be related to HPV vaccines, 203 had causality ratings of “certain” or “probable,” and 43 were defined as “serious.” Credit: Australian Government Department of Health and Aged Care. Japan withdraws recommendation, vaccine acceptance plunged In 2013, the Japanese raised concerns about a variety of widely reported post-vaccination serious adverse events. This led the government to suspend recommending the HPV vaccine for six years. Vaccine acceptance of HPV in Japan plunged significantly after 2013, from 42.9% to 14.3%, or from 65.4% to 3.9%. Researchers around the world also started to investigate HPV safety. A World Health Organization (WHO) position paper released on July 14, 2017, concluded that the HPV vaccines were “extremely safe.” The same report estimated approximately 1.7 cases of anaphylaxis per million HPV doses, that no association with GBS was found, and that syncope (fainting) was “established as a common anxiety or stress-related reaction to the injection.” In the spring of 2022, Japan announced it was relaunching its HPV vaccination drive. Mainstream news outlets reported that for thousands of women, the cost of caution may have led to preventable HPV-induced cancers and an estimated 5,000 to 5,700 deaths. However, a true risk-benefit analysis would also consider the number of serious adverse events prevented by putting the program on hold. The question remains: Was Japan’s caution warranted, or should their national vaccination program have continued? Ovarian insufficiency Concerns that the vaccine may be negatively affecting fertility have been detailed in the scientific literature. In 2014, a peer-reviewed case series describing premature ovarian failure among Australian women following HPV vaccination was published in the Journal of Investigative Medicine. This prompted other researchers to systematically examine the VAERS data to see if there was a connection between premature ovarian failure and Gardasil. Their study found a “potential safety signal” and concluded that “further investigations are warranted.” VAERS analysis on ovarian failure Two recent publications based on VAERS reports (first study, second study) found that events with a probable autoimmune background were significantly more frequent after HPV vaccination compared to other vaccinations. The team of international scientists that did the second study evaluated reports between 1990 and 2018. They found that among the 228,341 premature ovarian failure reports, 0.1% was considered to be associated with HPV vaccination with a median age of 15 years and the time to onset was 20.5 days following vaccination. The primary symptoms were amenorrhea (80.4%) and premature menopause (15.3%). Most strikingly, the mean number of premature ovarian failure cases increased significantly from 1.4 per year prior to 2006 to 22.2 per year after the HPV vaccine was approved, with a proportional reporting ratio of 46. The investigators noted that the WHO and CDC declared the HPV vaccine safe regardless of lacking adequate research into safety concerns. For example, the authors note that in a CDC-sponsored VAERS study, 17 cases of premature ovarian failure were identified but 15 were excluded due to insufficient information to confirm the diagnosis. A separate observational study using the Vaccine Safety Datalink found no increased risk. But this study was too underpowered to detect a signal. In addition, a cross-sectional survey study using National Health and Nutrition Examination Survey data relied on an inaccurate measurement of premature ovarian failure and self-reported HPV vaccination. In summary, the researchers detected a strong safety signal even after accounting for a potential upswing in reports due to media coverage after the product launch (they refer to this as “notoriety bias”). Because VAERS is a passive reporting system, the data may be incomplete and are often unconfirmed by physicians. Therefore, this study cannot provide a definitive link between HPV vaccination and premature ovarian insufficiency or premature ovarian failure but does generate a hypothetical link. The authors of the second study conclude by insisting that “this signal warrants well-designed and appropriate epidemiological research.” They note that “if the signal is confirmed, the risk is small compared to the lifetime risk of cervical cancer.” However, the benefit-risk profile on an individual level is not uniform. Given the health impacts of premature ovarian insufficiency and premature ovarian failure — some of which may be irreversible — and the declining mortality rate for cervical cancer even in the prevaccine era, the risk-benefit profile for HPV vaccination remains unclear. 3 case reports on ovarian insufficiency In the 2014 investigation mentioned above, a general practitioner in Australia noticed that three girls developed premature ovarian insufficiency following HPV4 vaccination. As a result of vaccination, each of the girls (ages 16, 16 and 18) had been prescribed oral contraception to treat menstrual cycle irregularities. Typically, women present with amenorrhea (no periods) or oligomenorrhea (infrequent periods) as the initial symptom of premature ovarian insufficiency. One girl had irregular periods following three doses of HPV vaccination. She then became amenorrheic and was diagnosed with premature ovarian insufficiency. Another girl’s periods were “like clockwork” until after the third HPV dose, which she received at age 15. Her first cycle after being vaccinated for the third time started two weeks late, and her next cycle was two months late. The final cycle began nine months later. The patient had no family history of early menopause. She was diagnosed with premature ovarian failure at 16. Lab work found hormone levels consistent with those of postmenopausal women, but her bone mineral density was normal. The authors of this case series noted that in preclinical studies of HPV4, the five-week-old rats only conceived one litter and the only available toxicology studies appear to be on the male rodent reproductive system. However, only two of three doses were administered prior to mating, and the overall fecundity was 95%, slightly lower than the control rats (98%) that received no vaccination prior to mating. The dose tolerance recommendations were based on an average weight of 50 kilograms for an adolescent girl but failed to take into account that HPV4 is administered to girls ages 9 to 13 years, who range in weight from 28 to 46 kilograms. Danish retrospective cohort study finds no link A 2021 study also evaluated premature ovarian insufficiency in a nationwide cohort of nearly 1 million Danish females ages 11 to 34 years. The researchers used Cox proportional hazard regression to detect an increased risk of premature ovarian insufficiency diagnosis by HPV4 vaccination status during the years 2007-2016. The hazard ratio for premature ovarian insufficiency (vaccinated versus unvaccinated) was 0.96. One limitation was that data on age at menarche (first menstruation) and oral contraceptive use were not available. Girls who had not yet reached menarche would not be at risk for premature ovarian insufficiency, of course. The authors excluded girls under age 15 in a sensitivity analysis and still found no signal, concluding that no association was found between HPV4 vaccination and premature ovarian insufficiency. Reprinted with permission from The Epoch Times. Dr. Yuhong Dong, a medical doctor who also holds a doctorate in infectious diseases from China, is the chief scientific officer and co-founder of a Swiss biotech company and a former senior medical scientific expert for antiviral drug development at Novartis Pharma in Switzerland. If you or your child suffered harm after receiving the Gardasil HPV vaccine, you may have a legal claim. Please visit Wisner Baum for a free case evaluation. Click here to watch a Gardasil litigation update interview with Wisner Baum Senior Partner Bijan Esfandiari. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the views of Children's Health Defense. https://childrenshealthdefense.org/defender/hpv-vaccine-safety-concerns-part-1-et/ https://donshafi911.blogspot.com/2024/01/the-truth-about-hpv-vaccination-part-1.html
    CHILDRENSHEALTHDEFENSE.ORG
    The Truth About HPV Vaccination, Part 1: How Safe Is It, Really?
    This first installment in a multi-part series about the human papillomavirus, or HPV, vaccine explores peer-reviewed scientific literature that reveals serious safety concerns about a vaccine widely regarded as safe.
    Like
    1
    0 Comentários 1 Compartilhamentos 15096 Visualizações
  • Bonjour à tous,
    Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents.
    --—
    S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après :
    https://markethive.com/christopheleroy/page/christopheleroy
    ------
    à propos de mon profil bio :
    https://markethive.com/christopheleroy
    ------
    Markethive, explications pour devenir Entrepreneur en français :
    https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais
    ------
    Markethive, explanations to become Entrepreneur (en) :
    https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur
    ------
    Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow
    ------
    Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive :
    https://www.youtube.com/watch?v=lQc8ANrPzDI
    ------
    Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire.
    NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels.
    ------
    #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Bonjour à tous, Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents. --— S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après : https://markethive.com/christopheleroy/page/christopheleroy ------ à propos de mon profil bio : https://markethive.com/christopheleroy ------ Markethive, explications pour devenir Entrepreneur en français : https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais ------ Markethive, explanations to become Entrepreneur (en) : https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur ------ Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow ------ Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive : https://www.youtube.com/watch?v=lQc8ANrPzDI ------ Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire. NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels. ------ #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Love
    1
    0 Comentários 0 Compartilhamentos 6940 Visualizações
  • Bonjour à tous,
    Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents.
    --—
    S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après :
    https://markethive.com/christopheleroy/page/christopheleroy
    ------
    à propos de mon profil bio :
    https://markethive.com/christopheleroy
    ------
    Markethive, explications pour devenir Entrepreneur en français :
    https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais
    ------
    Markethive, explanations to become Entrepreneur (en) :
    https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur
    ------
    Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow
    ------
    Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive :
    https://www.youtube.com/watch?v=lQc8ANrPzDI
    ------
    Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire.
    NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels.
    ------
    #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Bonjour à tous, Rejoignez-moi sur markethive, le réseau social & le réseau de marché construit sur la blockchain pour les entrepreneurs qui ont besoin de tous les outils afférents. --— S'inscrire sur markethive : (dans la partie bleue à gauche, en bas, cliquez sur un lien Learn more, si bien qu'une vidéo apparaitra longue et complète), où lire mon article ci-après : https://markethive.com/christopheleroy/page/christopheleroy ------ à propos de mon profil bio : https://markethive.com/christopheleroy ------ Markethive, explications pour devenir Entrepreneur en français : https://markethive.com/40353/blog/markethiveexplicationspourd%C3%A9marrerunprocessusdebusinessenfran%C3%A7ais ------ Markethive, explanations to become Entrepreneur (en) : https://markethive.com/40353/blog/markethiveexplanationstobecomeentrepreneur ------ Your Wallet - KYC (Know Your Customer) : markethive.com/group/marketingdept/blog/aboutthemarkethivewalletwhatyouneedtoknow ------ Lancement de la statégie ICO, ILP & hivecoin par Thomas Prendergast, CEO de Markethive : https://www.youtube.com/watch?v=lQc8ANrPzDI ------ Je suis Entrepreneur One à 100$ par mois qui n'est pas obligatoire. NOTE IMPORTANTE: Vous devrez prouver votre identité en envoyant les documents requis. En conséquence, les inscrits, les utilisateurs sont réels. ------ #entrepreneur #profits #gains #marketing #internetmarketing #networkmarketing #bitcoin #btc #litecoin #crypto #digitalmarketing #business #independent #sells #techniques #partner #technologies #affiliatemarketing #advertising #markethive #socialmedia #marketmedia #inboundmarketing #hivecoin #ILP #Markethivecoin
    Love
    1
    0 Comentários 0 Compartilhamentos 6897 Visualizações
Páginas impulsionada